RESEARCH OPPORTUNITIES ALERT

Issue 28: Volume 1b

GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)

(Quarter: January - March, 2017)

A Compilation by the

RESEARCH SERVICES UNIT
OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID)
UNIVERSITY OF GHANA

JANUARY 2017

- Research Grants
- Innovation Grants
- Academic-Industry Grants
- Collaborative Opportunities
- Technology Development Grants

TABLE OF CONTENT

OPPORTUNITIES FOR JANUARY 2017

BRAIN INITIATIVE CELL CENSUS NETWORK – SPECIALISED COLLABORATORY ON MOUSE BRAIN CELL ATLAS (U01) 18

BRAIN INITIATIVE CELL CENSUS NETWORK – SPECIALISED COLLABORATORY ON HUMAN AND NON-HUMAN PRIMATE BRAIN CELL ATLASES (U01) 18

BRAIN INITIATIVE CELL CENSUS NETWORK – BRAIN CELL DATA CENTRE (U24) 18

BRAIN INITIATIVE CELL CENSUS NETWORK – COMPREHENSIVE CENTRE ON MOUSE BRAIN CELL ATLAS (U19) 19

CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1) 19

CLINICAL VISION RESEARCH: CHAIR'S GRANT (UG1) 20

CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1) 20

CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1) 20

GENOMIC RESOURCE GRANTS FOR COMMUNITY RESOURCE PROJECTS (U41) 21

PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIOURAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01) 21

BRAIN INITIATIVE: RESEARCH ON THE ETHICAL IMPLICATIONS OF ADVANCEMENTS IN NEUROTECHNOLOGY AND BRAIN SCIENCE (R01) 21

OPPORTUNITIES FOR FEBRUARY 2017

MECHANISM FOR TIME-SENSITIVE RESEARCH OPPORTUNITIES IN ENVIRONMENTAL HEALTH SCIENCES (R21) 22

SERIOUS ADVERSE DRUG REACTION RESEARCH (R21) 22

SERIOUS ADVERSE DRUG REACTION RESEARCH (R01) 22

EXTENDED DEADLINE: BRAIN INITIATIVE: PROOF OF CONCEPT DEVELOPMENT OF EARLY STAGE NEXT GENERATION HUMAN BRAIN IMAGING (R01) 23

EXTENDED DEADLINE: BRAIN INITIATIVE: DEVELOPMENT OF NEXT GENERATION HUMAN BRAIN IMAGING TOOLS AND TECHNOLOGIES (U01) 23

SHORT-TERM MEASUREMENTS OF PHYSICAL RESILIENCE AS A PREDICTOR OF HEALTHSPAN IN MICE (R01) 24

EXOSOMES: FROM BIOGENESIS AND SECRETION TO THE EARLY PATHOGENESIS OF ALZHEIMER'S DISEASE (R01) 24

ENHANCING THE TARGET AND BIOMARKER DISCOVERY EFFORTS OF THE AMP-AD AND M2OVE-AD CONSORTIA (R01) 24

PRAGMATIC TRIALS FOR DEMENTIA CARE IN LONG-TERM SERVICES AND SUPPORT SETTINGS (R21/R33) 25

PRAGMATIC TRIALS FOR DEMENTIA CARE IN LONG-TERM SERVICES AND SUPPORT SETTINGS (R01) 25

DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01) 25

GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01) 26

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01) 26

PRESCRIPTION DRUG ABUSE (R01) 26

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01) 27

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01) 27

BIOENGINEERING RESEARCH GRANTS (R01) 28

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R01) 28

OCCUPATIONAL SAFETY AND HEALTH RESEARCH (R01) 28

MODELLING OF INFECTIOUS DISEASE AGENT STUDY RESEARCH PROJECTS (R01) 29

ADVANCING ERYTHROID CELL BIOLOGY (R01) 29

LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH REGULAR RESEARCH PROGRAMME (R01) 29

ANCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01) 30

ADDRESSING HEALTH DISPARITIES IN NIDDK DISEASES (R01) 30

MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01) 30

RESEARCH PROJECT GRANT (PARENT R01) 31

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01) 31

BIOLOGY OF MANUAL THERAPIES (R01) 31

NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01) 32

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01) 32

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01) 32

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01) 33

INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01) 33

PROGRAMME FOR EXTRAMURAL OR INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01) 33

NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01) 34

EPIDEMIOLOGY OF DRUG ABUSE (R01) 34

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01) 34

INVESTIGATIONS ON PRIMARY IMMUNODEFICIENCY DISEASES (R01) 35
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01) 35
METHODOLOGY AND MEASUREMENT IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01) ...35
QUANTITATIVE IMAGING FOR EVALUATION OF RESPONSES TO CANCER THERAPIES (U01) 36
RESEARCH TO ADVANCE VACCINE SAFETY (R01) 36
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01) 36
ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01) 37
OBESITY POLICY EVALUATION RESEARCH (R01) 37
SELECTED TOPICS IN TRANSFUSION MEDICINE (R01) 37
STIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (R01) 38
ADVANCES IN POLYCYSTIC KIDNEY DISEASE (R01) 38
MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R01) 38
RESEARCH ON AUTISM SPECTRUM DISORDERS (R01) 39
NATURAL HISTORY OF DISORDERS IDENTIFIABLE BY NEWBORN SCREENING (R01) 39
HIV INCIDENCE ASSAYS WITH IMPROVED SPECIFICITY (R01) 39
RESEARCH ON HEARING HEALTHCARE (R01) 40
NEUROBIOLOGY OF MIGRAINE (R01) 40
PRECLINICAL RESEARCH ON MODEL ORGANISMS TO PREDICT TREATMENT OUTCOMES FOR DISORDERS ASSOCIATED WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01) 40
OUTCOME MEASURES FOR USE IN TREATMENT TRIALS FOR INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01) 41
ANCILLARY STUDIES TO THE NIDDK INTESTINAL STEM CELL CONSORTIUM (R01) 41
FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01) 41
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01) 42
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01) 42
OBESITY AND ASTHMA: AWARENESS AND SELF-MANAGEMENT (R01) 42
MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01) 43
MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01) 43
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01) 43
BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01) 44
BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01) 44
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01) 44

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) 45

ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01) 45

MECHANISMS MEDIATING OSTEOARTHRITIS IN AGEING (R01) 45

DISCOVERY OF IN VIVO CHEMICAL PROBES (R01) 46

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01) 46

MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01) 46

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01) 47

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01) 47

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01) 47

CLINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01) 48

LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01) 48

EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01) 48

IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R01) 49

EARLY-STAGE PRECLINICAL VALIDATION OF THERAPEUTIC LEADS FOR DISEASES OF INTEREST TO THE NIDDK (R01) 49

EXTENDED DEADLINE: ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01) 49

PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01) 50

NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01) 50

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01) 50

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01) 51

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01) 51

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01) 51

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01) 52

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01) 52

ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01) 52

EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01) 53

EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01) 53

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01) 53

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01) 54

CLINICAL STUDIES OF MENTAL ILLNESS NOT INVOLVING TREATMENT DEVELOPMENT, EFFICACY OR EFFECTIVENESS TRIALS (COLLABORATIVE R01) 54

NIH STROKENET CLINICAL TRIALS AND BIOMARKER STUDIES FOR STROKE TREATMENT, RECOVERY AND PREVENTION (U01) 54

CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) 55

ADVANCING RESEARCH IN VOICE DISORDERS (R01) 55

COLLABORATIVE RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MAMMALIAN MODELS FOR TRANSLATIONAL RESEARCH (COLLABORATIVE R01) 56

RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MAMMALIAN MODELS FOR TRANSLATIONAL RESEARCH (R01) 56

RESEARCH ON CHRONIC OVERLAPPING PAIN CONDITIONS (R01) 56

ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01) 57

UNDERSTANDING FACTORS IN INFANCY AND EARLY CHILDHOOD THAT INFLUENCE OBESITY DEVELOPMENT (R01) 57

SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01) 57

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01) 58

BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01) 58

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01) 58

RESEARCH ON EOSINOPHIL ASSOCIATED DISORDERS (R01) 59

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01) 59

NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01) 59

ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01) 60

PREVENTION RESEARCH IN MID-LIFE ADULTS (R01) 60

ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01) 60

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01) 61

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R01) 61

IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01) 61

DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01) 62

STUDIES AT PERIVIABLE GESTATION (R01) 62

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R01) 62

BIOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01) 63

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01) 63

RESEARCH ON THE MECHANISMS OR BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01) 63

PHASE III CLINICAL TRIALS FOR THE SPECTRUM OF ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE (R01) 64

PILOT CLINICAL TRIALS FOR THE SPECTRUM OF ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE (R01) 64

EMERGING DIRECTIONS FOR ADDRESSING HEALTH DISPARITIES IN ALZHEIMER'S DISEASE (R03) 64

RESEARCH ON INFORMAL AND FORMAL CAREGIVING FOR ALZHEIMER'S DISEASE (R21) 65

HEALTH DISPARITIES AND ALZHEIMER'S DISEASE (R01) 65

MAJOR OPPORTUNITIES FOR RESEARCH IN EPIDEMIOLOGY OF ALZHEIMER'S DISEASE AND COGNITIVE RESILIENCE (R01) 65

RESEARCH ON INFORMAL AND FORMAL CAREGIVING FOR ALZHEIMER'S DISEASE (R01) 66

UNDERSTANDING ALZHEIMER'S DISEASE IN THE CONTEXT OF THE AGEING BRAIN (R01) 66

CAPTURING COMPLEXITY IN THE MOLECULAR AND CELLULAR MECHANISMS INVOLVED IN THE AETIOLOGY OF ALZHEIMER'S DISEASE (R01) 66

NOVEL APPROACHES TO DIAGNOSING ALZHEIMER'S DISEASE AND PREDICTING PROGRESSION (R01) 67

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01) 67

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01) 67

APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R01) ..68

ASSAY DEVELOPMENT AND SCREENING TO DISCOVER THERAPEUTIC OR IMAGING AGENTS FOR DISEASES OF INTEREST TO THE NIDDK (R01) 75

ENGINEERING NEXT-GENERATION HUMAN NERVOUS SYSTEM MICROPHYSIOLOGICAL SYSTEMS (R01) 76

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01) 76

SYMPTOM MANAGEMENT IN HIV-INFECTED INDIVIDUALS WITH COMORBID CONDITIONS (R01) 76

BASIC AND TRANSLATIONAL RESEARCH ON DECISION MAKING IN AGEING AND ALZHEIMER'S DISEASE (R01) 77

TROPHOBLAST DIFFERENTIATION AND FUNCTION (R01) 77

PALLIATIVE CARE NEEDS OF INDIVIDUALS WITH RARE ADVANCED DISEASES AND THEIR FAMILY CAREGIVERS (R01) 77

IMPROVING INDIVIDUAL AND FAMILY OUTCOMES THROUGH CONTINUITY AND CO-ORDINATION OF CARE IN HOSPICE (R01) 78

ADDRESSING UNMET NEEDS IN PERSONS WITH DEMENTIA TO DECREASE BEHAVIOURAL SYMPTOMS AND IMPROVE QUALITY OF LIFE (R01) 78

SELF-MANAGEMENT INTERVENTIONS AND TECHNOLOGIES TO SUSTAIN HEALTH AND OPTIMISE FUNCTIONAL CAPABILITIES (R01) 78

USE OF TECHNOLOGY TO ENHANCE PATIENT OUTCOMES AND PREVENT ILLNESS (R01) 79

COMMON MECHANISMS AND INTERACTIONS AMONG NEURODEGENERATIVE DISEASES (R01) 79

IMPROVING QUALITY OF CARE AND QUALITY OF LIFE FOR PERSONS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS AT THE END OF LIFE (R01) 79

DYNAMIC INTERACTIONS BETWEEN SYSTEMIC OR NON-NEURONAL SYSTEMS AND THE BRAIN IN AGEING AND IN ALZHEIMER'S DISEASE (R01) 80

INTEGRATIVE RESEARCH TO UNDERSTAND THE IMPACT OF SEX DIFFERENCES ON THE MOLECULAR DETERMINANTS OF ALZHEIMER'S DISEASE RISK AND RESPONSIVENESS TO TREATMENT (R01) 80

TRANSLATIONAL BIOINFORMATICS APPROACHES TO ADVANCE DRUG REPOSITIONING AND COMBINATION THERAPY DEVELOPMENT FOR ALZHEIMER'S DISEASE (R01) 80

ROLE OF AGE-ASSOCIATED METABOLIC CHANGES IN ALZHEIMER'S DISEASE (R01) 81

CLARIFIYING THE RELATIONSHIP BETWEEN DELIRIUM AND ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (R01) 81

SELECTIVE CELL AND NETWORK VULNERABILITY IN AGEING AND ALZHEIMER'S DISEASE (R01) 81

LEVERAGING EXISTING COHORT STUDIES TO CLARIFY RISK AND PROTECTIVE FACTORS FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (R01) 82

ORAL ANTICANCER AGENTS: UTILISATION, ADHERENCE AND HEALTH CARE DELIVERY (R01) 82

BASIC MECHANISMS OF BRAIN DEVELOPMENT MEDIATING SUBSTANCE USE AND DEPENDENCE (R01) 82

CANCER-RELATED BEHAVIOURAL RESEARCH THROUGH INTEGRATING EXISTING DATA (R01) 83

NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01) 83

NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3) 83

BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)....84

NIDCD PHASE III CLINICAL TRIALS IN COMMUNICATION DISORDERS (U34)....84

NIDCD PLANNING GRANT FOR PHASE III CLINICAL TRIALS IN COMMUNICATION DISORDERS (U34) 84

EARLY PHASE CLINICAL TRIALS IN IMAGING AND IMAGE-GUIDED INTERVENTIONS (R01)....85

BRAIN LYMPHATIC SYSTEM IN AGEING AND ALZHEIMER'S DISEASE (R01) 85

EXPLORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34)....85

HUMAN CELL BIOLOGY OF GENETIC VARIANTS IN ALZHEIMER'S DISEASE (R01)....86

UNDERSTANDING THE EFFECTS OF APOLIPOPROTEIN E 2 ON THE INTERACTION BETWEEN AGEING AND ALZHEIMER'S DISEASE (R01) 86

LEVERAGING EXISTING RESOURCES FOR RESEARCH ON LEWY BODY DEMENTIA (R03) 86

FRONTOTEMPORAL DEGENERATION SEQUENCING CONSORTIUM: DISCOVERY, REPLICATION AND VALIDATION (UG3/UH3) 87

SINGLE-SITE INVESTIGATOR-INITIATED CLINICAL TRIALS (R61/R33)....87

NOVEL ANALYTICAL APPROACHES FOR METABOLOMICS DATA (R03) 87

UTILISING THE PLCO BIOSPECIMENS RESOURCE TO BRIDGE GAPS IN CANCER AETIOLOGY AND EARLY-DETECTION RESEARCH (U01)....88

DEVELOPMENT OF PSYCHOSOCIAL THERAPEUTIC AND PREVENTIVE INTERVENTIONS FOR MENTAL DISORDERS (R61/R33)....88

DEVELOPMENT OF PSYCHOSOCIAL THERAPEUTIC AND PREVENTIVE INTERVENTIONS FOR MENTAL DISORDERS (R33)....88

CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R01)....89

CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (COLLABORATIVE R01) 89

PILOT EFFECTIVENESS TRIALS FOR TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R34)....89

CONFIRMATORY EFFICACY CLINICAL TRIALS OF NON-PHARMACOLOGICAL INTERVENTIONS FOR MENTAL DISORDERS (R01)....90

CANCER-RELATED BEHAVIOURAL RESEARCH THROUGH INTEGRATING EXISTING DATA (R21) 90

SUMMER CURRICULUM IN CANCER....90

EARLY STAGE TESTING OF PHARMACOLOGIC OR DEVICE-BASED INTERVENTIONS FOR THE TREATMENT OF MENTAL DISORDERS (R33)....91

NEI RESEARCH GRANT FOR VISION RELATED SECONDARY DATA ANALYSIS (R21) 91

IMAGING – SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03) 91
EXPLORATORY OR DEVELOPMENTAL RESEARCH GRANT PROGRAMME (PARENT R21) 92
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21)....92
SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21) 92
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21) 93
ETHICAL, LEGAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH SMALL RESEARCH GRANT PROGRAMME (R03) 93
EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21) 93
SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT (R03)....94
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R21) 94
SMALL RESEARCH GRANT PROGRAMME (PARENT R03) 94
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21) 95
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03) 95
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R21) 95
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03) 96
BIOLOGY OF MANUAL THERAPIES (R21) 96
RESEARCH ON AUTISM SPECTRUM DISORDERS (R03) 96
RESEARCH ON AUTISM SPECTRUM DISORDERS (R21) 97
PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21) 97
EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21) 97
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03)....98
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21) 98
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21) 98
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21)....99
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03)....99
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21) 99
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03) 100
DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21)....100
REDUCING HEALTH DISPARITIES AMONG MINORITY AND UNDERSERVED CHILDREN (R21) .100

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21) 101
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03) 101
GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R03) 101
GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R21) 102
SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03) 102
EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21) 102
EPIDEMIOLOGY OF DRUG ABUSE (R21) 103
EPIDEMIOLOGY OF DRUG ABUSE (R03) 103
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03) 103
BEHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34) 104
RESEARCH TO ADVANCE VACCINE SAFETY (R21) 104
PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG AND ALCOHOL ABUSE PREVENTION TRIALS (R34) 104
DIET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R21) 105
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34) 105
NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34) 105
SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03) 106
DEADLINE BROUGHT FORWARD: SELECTED TOPICS IN TRANSFUSION MEDICINE (R21) 106
MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R03) 106
MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R21) 107
RESEARCH ON HEARING HEALTHCARE (R21) 107
NEUROBIOLOGY OF MIGRAINE (R21) 107
CHEMICAL DISCOVERY AWARD (R21/R33) 108
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03) 108
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21) 108
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21) 109
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21) 109
SPATIAL UNCERTAINTY: DATA, MODELLING AND COMMUNICATION (R03) 109
LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH EXPLORATORY/DEVELOPMENTAL RESEARCH PROGRAMME (R21) 110
MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21) 110
SYSTEMS SCIENCE AND HEALTH IN BEHAVIOURAL AND SOCIAL SCIENCES (R21) 110

HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21) 111

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21) 111

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03) 111

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21) 112

PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34) 112

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R21) 112

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS – EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21) 113

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21) 113

EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21) 114

DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03) 114

IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R21) 114

SMALL RESEARCH GRANTS FOR SECONDARY ANALYSIS OF FACEBASE DATA (R03) 115

EXTENDED DEADLINE: ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21) 115

NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21) 115

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03) 116

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21) 116

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21) 116

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21) 117

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34) 117

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21) 117

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21) 118

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21) 118

ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21) 118

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21) 119

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21) 119

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03) 119
ADVANCING RESEARCH IN VOICE DISORDERS (R21).....120
RESEARCH ON CHRONIC OVERLAPPING PAIN CONDITIONS (R21) 120
HIGH THROUGHPUT SCREENING (HTS) TO DISCOVER CHEMICAL PROBES (R21) 120
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03) 121
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21) 121
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21).....121
NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34).....122
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21) 122
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21).....122
RESEARCH ON EOSINOPHIL ASSOCIATED DISORDERS (R21) 123
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03).....123
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21).....123
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33) 124
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33) 124
PREVENTION RESEARCH IN MID-LIFE ADULTS (R21) 125
REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33).....125
NOVEL BIOMARKERS FOR THE DEVELOPMENT OF HIV INCIDENCE ASSAYS WITH IMPROVED SPECIFICITY (R21).....125
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03) 126
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21) 126
FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R21) 126
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21) 127
IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21) 127
STUDIES AT PERIVIABLE GESTATION (R03) 127
STUDIES AT PERIVIABLE GESTATION (R21) 128
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03) 128
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R21) 128

PILOT SERVICES RESEARCH GRANTS NOT INVOLVING INTERVENTIONS (R34) 129

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R21) 129

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R21) 129

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R21) 130

APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R21) 130

ADVANCING UNDERSTANDING, PREVENTION AND MANAGEMENT OF INFECTIONS TRANSMITTED FROM WOMEN TO THEIR INFANTS (R21) 130

IMPROVING OUTCOMES IN CANCER TREATMENT-RELATED CARDIOTOXICITY (R21) 131

OOCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R21) 131

ACCELERATING RESEARCH ON INTERVERTEBRAL DISC (R21) 131

USING THE NIMH RESEARCH DOMAIN CRITERIA APPROACH TO UNDERSTAND PSYCHOSIS (R21) 132

ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R21) 132

POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R21) 132

TAILORING DENTAL TREATMENT FOR INDIVIDUALS WITH SYSTEMIC DISEASES THAT COMPROMISE ORAL HEALTH (R21) 133

EXTENDED DEADLINE: PILOT AND FEASIBILITY STUDIES EVALUATING THE ROLE OF RIBONUCLEIC ACID MODIFICATIONS IN CANCER BIOLOGY (R21) 133

ROLE OF MOBILE GENETIC ELEMENTS IN CANCER (R21) 133

METABOLIC REPROGRAMMING TO IMPROVE IMMUNOTHERAPY (R21) 134

NON-HEALING ULCERATIVE WOUNDS IN AGEING (R21) 134

MECHANISMS MEDIATING OSTEOARTHRITIS IN AGEING (R21) 134

NOVEL APPROACHES TO UNDERSTANDING, PREVENTING AND TREATING LYME DISEASE AND TICK-BORNE COINFECTIONS (R21) 135

GENE FUSION IN PAEDIATRIC SARCOMAS (R21) 135

MECHANISMS OF CANCER AND TREATMENT-RELATED SYMPTOMS AND TOXICITIES (R21) ... 136

STIMULATING INNOVATIONS IN BEHAVIOURAL INTERVENTION RESEARCH FOR CANCER PREVENTION AND CONTROL (R21) 136

INTEGRATIVE RESEARCH ON POLYSUBSTANCE ABUSE AND ADDICTION (R21/R33) 136

INTEGRATIVE RESEARCH ON POLYSUBSTANCE ABUSE AND ADDICTION (R21/R33): AIDS-RELATED 137

FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R21) 137

FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R21): AIDS-RELATED 137

CHARACTERISATION OF THE ADOLESCENT REPRODUCTIVE TRANSITION (R03) 138

CHARACTERISATION OF THE ADOLESCENT REPRODUCTIVE TRANSITION (R21) 138

SAFETY AND OUTCOME MEASURES OF PAIN MEDICATIONS USED IN CHILDREN AND PREGNANT WOMEN (R03) 138

SAFETY AND OUTCOME MEASURES OF PAIN MEDICATIONS USED IN CHILDREN AND PREGNANT WOMEN (R21) 139

SMALL RESEARCH GRANTS FOR ANALYSES OF DATA FOR THE GABRIELLA MILLER KIDS FIRST DATA RESOURCE (R03) 139

TARGET ASSESSMENT, ENGAGEMENT AND DATA REPLICABILITY TO IMPROVE SUBSTANCE USE DISORDERS TREATMENT OUTCOMES (R33) 139

TARGET ASSESSMENT, ENGAGEMENT AND DATA REPLICABILITY TO IMPROVE SUBSTANCE USE DISORDERS TREATMENT OUTCOMES (R21/R33) 140

PHENOTYPIC AND FUNCTIONAL CHARACTERISATION OF APOLIPOPROTEIN E TWO TO INFORM TRANSLATION STRATEGIES FOR AGEING-RELATED CONDITIONS (R21) 140

ENGINEERING NEXT-GENERATION HUMAN NERVOUS SYSTEM MICROPHYSIOLOGICAL SYSTEMS (R21) 140

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03) 141

SYMPTOM MANAGEMENT IN HIV-INFECTED INDIVIDUALS WITH COMORBID CONDITIONS (R21) 141

BASIC AND TRANSLATIONAL RESEARCH ON DECISION MAKING IN AGEING AND ALZHEIMER'S DISEASE (R21) 141

TROPHOBLAST DIFFERENTIATION AND FUNCTION (R21) 142

PALLIATIVE CARE NEEDS OF INDIVIDUALS WITH RARE ADVANCED DISEASES AND THEIR FAMILY CAREGIVERS (R21) 142

IMPROVING INDIVIDUAL AND FAMILY OUTCOMES THROUGH CONTINUITY AND CO-ORDINATION OF CARE IN HOSPICE (R21) 142

ADDRESSING UNMET NEEDS IN PERSONS WITH DEMENTIA TO DECREASE BEHAVIOURAL SYMPTOMS AND IMPROVE QUALITY OF LIFE (R21) 143

SELF-MANAGEMENT INTERVENTIONS AND TECHNOLOGIES TO SUSTAIN HEALTH AND OPTIMISE FUNCTIONAL CAPABILITIES (R21) 143

USE OF TECHNOLOGY TO ENHANCE PATIENT OUTCOMES AND PREVENT ILLNESS (R21) 143

IMPROVING QUALITY OF CARE AND QUALITY OF LIFE FOR PERSONS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS AT THE END OF LIFE (R03) 144

CLARIFYING THE RELATIONSHIP BETWEEN DELIRIUM AND ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (R21/R33) 144

ORAL ANTICANCER AGENTS: UTILISATION, ADHERENCE AND HEALTH CARE DELIVERY (R21) 144

CLINICAL TRIAL READINESS FOR RARE NEUROLOGICAL AND NEUROMUSCULAR DISEASES (U01) 145

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS – DEVELOPMENT AND VALIDATION OF MODEL SYSTEMS AND PHARMACODYNAMIC MARKERS TO FACILITATE THE DISCOVERY OF NEUROTHERAPEUTICS (R21/R33) 145

DEADLINE BROUGHT FORWARD: CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21) 145

INTERDISCIPLINARY RESEARCH TO UNDERSTAND THE COMPLEX BIOLOGY OF RESILIENCE TO ALZHEIMER'S DISEASE RISK (R01) 146

PLANNING GRANT FOR EMERGING EPIDEMIC VIRUS RESEARCH TRAINING FOR WEST AFRICAN COUNTRIES WITH WIDESPREAD TRANSMISSION OF EBOLA – GUINEA, LIBERIA AND SIERRA LEONE (D71) 146

EXTENDED DEADLINE: GLOBAL NON-COMMUNICABLE DISEASES AND INJURY ACROSS THE LIFESPAN: EXPLORATORY RESEARCH (R21) 146

NEURAL REGULATION OF CANCER (R21) 147

NEURAL REGULATION OF CANCER (R01) 147

RESEARCH GRANTS FOR TRANSLATING BASIC RESEARCH INTO CLINICAL TOOLS (R01) 148

NOVEL ASSAYS TO ADDRESS TRANSLATIONAL GAPS IN TREATMENT DEVELOPMENT (UG3/UH3) 148

1440 AWARDS FOR CONTEMPLATIVE EDUCATION RESEARCH 148

SECONDARY ANALYSES OF EXISTING DATASETS IN HEART, LUNG AND BLOOD DISEASES AND SLEEP DISORDERS (R21) 149

ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING BIOSPECIMEN SCIENCE TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33) 149

INNOVATIVE TECHNOLOGIES FOR CANCER-RELEVANT BIOSPECIMEN SCIENCE (R21) 149

ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33) 150

INNOVATIVE MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R21) 150

OPPORTUNITIES FOR MARCH 2017

IDENTIFICATION OF GENETIC AND GENOMIC VARIANTS BY NEXT-GEN SEQUENCING IN NON-HUMAN ANIMAL MODELS (U01) 151

BIOLOGICAL COMPARISONS IN PATIENT-DERIVED MODELS OF CANCER (U01) 151

ACADEMIC-INDUSTRIAL PARTNERSHIPS TO TRANSLATE AND VALIDATE IN VIVO CANCER IMAGING SYSTEMS (R01) 151

ADMINISTRATIVE SUPPLEMENTS FOR RESEARCH ON SEXUAL AND GENDER MINORITY POPULATIONS 152

PARTNERSHIPS FOR DEVELOPMENT OF VACCINES TO PREVENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND TUBERCULOSIS DISEASE (R01) 152

T CELL REAGENT RESEARCH FOR THE STUDY OF ALLERGIC DISEASES (U19) 153

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) 153

INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01) 153

BRAIN INITIATIVE: EXPLORATORY TARGETED BRAIN CIRCUITS PROJECTS – ETARGETEDBCP (R21) 154

BRAIN INITIATIVE: TARGETED BRAIN CIRCUITS PROJECTS – TARGETEDBCP (R01) 154

INTEGRATED PRECLINICAL AND CLINICAL AIDS VACCINE DEVELOPMENT PROGRAMME (U19) 154

CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01) 155

PILOT CLINICAL TRIALS TARGETING HIV-1 RESERVOIRS IN CHILDREN (U01) 155

PLANNING FOR NON-COMMUNICABLE DISEASES AND DISORDERS RESEARCH TRAINING PROGRAMMES IN LOW AND MIDDLE INCOME COUNTRIES (D71) 155

BRAIN INITIATIVE FELLOWS: RUTH L KIRSCHSTEIN NATIONAL RESEARCH SERVICE AWARD INDIVIDUAL POSTDOCTORAL FELLOWSHIP (F32) 156

SYSTEMS BIOLOGY: THE NEXT GENERATION FOR INFECTIOUS DISEASES (U19) 156

DEVELOPMENT OF MULTIPURPOSE PREVENTION TECHNOLOGIES: A STRATEGY FOR THE PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS (R61/R33) 156

SMALL-CELL LUNG CANCER CONSORTIUM: THERAPEUTIC DEVELOPMENT AND MECHANISMS OF RESISTANCE (U01) 157

SMALL-CELL LUNG CANCER CONSORTIUM: INNOVATIVE APPROACHES TO THE PREVENTION AND EARLY DETECTION OF SMALL CELL LUNG CANCER (U01) 157

NINDS EXPLORATORY CLINICAL TRIALS (R01) 157

CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21): AIDS-RELATED 158

THERAPEUTIC TARGETING OF THE HUMAN ISLET ENVIRONMENT (UC4) 158

COMPETITIVE COLLABORATIVE PROJECTS FOR HUMAN ISLET BIOLOGY (UC4) 158

SECONDARY ANALYSES OF EXISTING DATASETS IN HEART, LUNG AND BLOOD DISEASES AND SLEEP DISORDERS (R21): AIDS-RELATED 159

STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01) 159

GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01) 159

FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3) 160

MOVING BEYOND STANDARD ASSESSMENTS: APPLYING NOVEL TOOLS TO ASSESS HUMAN PLACENTAL STRUCTURE AND FUNCTION IN REAL TIME (R01) 160

MOVING BEYOND STANDARD ASSESSMENTS: APPLYING NOVEL TOOLS TO ASSESS HUMAN PLACENTAL STRUCTURE AND FUNCTION IN REAL TIME (R21) 160

JANUARY 2017

BRAIN INITIATIVE CELL CENSUS NETWORK – SPECIALISED COLLABORATORY ON MOUSE BRAIN CELL ATLAS (U01)

NIH: National Institute of Mental Health

This supports specialised collaboratory that will adopt scalable technology platforms and streamlined workflows to generate a comprehensive 3D brain cell reference atlas encompassing molecular, anatomical, and physiological annotations of brain cell types in mouse, and incorporate additional genetic and other advanced cell-specific targeting approaches and tools to facilitate this goal. Application budgets are not limited but need to reflect the actual needs of the proposed budget. The maximum project period is five years.

Closing date: 23 Jan 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-230.html

BRAIN INITIATIVE CELL CENSUS NETWORK – SPECIALISED COLLABORATORY ON HUMAN AND NON-HUMAN PRIMATE BRAIN CELL ATLASES (U01)

NIH: National Institute of Mental Health

This intends to assemble a group of specialised collaboratories that will adopt scalable technology platforms and streamlined workflows to accelerate progress towards establishing reference cell atlases of human brain and non-human primate brains. Application budgets are not limited but need to reflect the actual needs of the proposed budget. The maximum project period is five years.

Closing date: 23 Jan 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-210.html

BRAIN INITIATIVE CELL CENSUS NETWORK – BRAIN CELL DATA CENTRE (U24)

NIH: National Institute of Mental Health

This intends to support brain cell data center that will work with other BICCN centres and interested researchers to establish a web-accessible information system to capture, store,

analyze, curate, and display all data and metadata on brain cell types, and their connectivity. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 23 Jan 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-215.html

BRAIN INITIATIVE CELL CENSUS NETWORK – COMPREHENSIVE CENTRE ON MOUSE BRAIN CELL ATLAS (U19)

NIH: National Institute of Mental Health

This intends to assemble a group of comprehensive centres that will adopt scalable technology platforms and streamlined workflows to generate a comprehensive 3D brain cell reference atlas encompassing molecular, anatomical, and physiological annotations of brain cell types in mouse, and incorporate additional genetic and other advanced cell-specific targeting approaches and tools to facilitate this goal. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is 5 years.

Closing date: 23 Jan 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-225.html

CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1)

NIH: National Eye Institute

This UG1 funding opportunity announcement supports single component resource centres to provide imaging, laboratory or other requisite services for a multi-centre clinical trial or other complex or high-risk clinical vision research study. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 25 Jan 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-097.html

CLINICAL VISION RESEARCH: CHAIR'S GRANT (UG1)

NIH: National Eye Institute

This UG1 funding opportunity announcement supports the scientific rationale, study aims and significance of the research project. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 25 Jan 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-098.html

CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1)

NIH: National Eye Institute

This UG1 funding opportunity announcement supports the organisation and operations of the clinical centre responsible for recruitment and retention of study participants and implementation of the study protocol. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 25 Jan 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-099.html

CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1)

NIH: National Eye Institute

This UG1 funding opportunity announcement supports the provision of details of the coordinating centre's responsibilities and operations. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 25 Jan 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-100.html

GENOMIC RESOURCE GRANTS FOR COMMUNITY RESOURCE PROJECTS (U41)

NIH: National Human Genome Research Institute

This U41 funding announcement supports the development and distribution of genomic resources that will be available to and valuable for the broad research community, using cost-effective approaches. Application budgets are not limited, but should reflect the needs of the proposed project over a maximum period of five years.

Closing date: 25 Jan 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-191.html

PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIOURAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01)

NIH: National Institute of Biomedical Imaging and Bioengineering

This announcement aims to support the development of multiscale models to accelerate biological, biomedical, behavioral, environmental and clinical research. Direct costs are limited to US$500,000 per year and the maximum project period is five years.

Closing date: 30 Jan 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-085.html

BRAIN INITIATIVE: RESEARCH ON THE ETHICAL IMPLICATIONS OF ADVANCEMENTS IN NEUROTECHNOLOGY AND BRAIN SCIENCE (R01)

NIH: National Institute of Mental Health

This supports efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements in research and development supported by the BRAIN Initiative. Application budgets are worth up to USD 300,000 in direct costs in any year. The maximum project period is four years.

Closing date: 30 Jan 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-260.html

FEBRUARY 2017

MECHANISM FOR TIME-SENSITIVE RESEARCH OPPORTUNITIES IN ENVIRONMENTAL HEALTH SCIENCES (R21)

NIH: National Institute of Environmental Health Sciences

This announcement supports environmental health research in which an unpredictable event provides a limited window of opportunity to collect human biological samples or environmental exposure data. Application budgets are limited to US$275,000 for a maximum period of two years. No more than US$200,000 may be requested in a single year.

Closing date: 01 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-16-005.html

SERIOUS ADVERSE DRUG REACTION RESEARCH (R21)

NIH: National Human Genome Research Institute

This R21 funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. The maximum project period is two years.

Closing date: 01 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-274.html

SERIOUS ADVERSE DRUG REACTION RESEARCH (R01)

NIH: National Human Genome Research Institute

This R01 funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is four years.
Closing date: 01 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-275.html

EXTENDED DEADLINE: BRAIN INITIATIVE: PROOF OF CONCEPT DEVELOPMENT OF EARLY STAGE NEXT GENERATION HUMAN BRAIN IMAGING (R01)

NIH: National Institute of Biomedical Imaging and Bioengineering

*** The closing date for this opportunity has been extended. The previous deadline of 20 January has been extended to 1 February 2017. All other call details remain unchanged. This call aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. Application budgets are worth up to USD 300,000 in direct costs in any year. The maximum project period is two years. ***

Closing date: 01 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-17-001.html

EXTENDED DEADLINE: BRAIN INITIATIVE: DEVELOPMENT OF NEXT GENERATION HUMAN BRAIN IMAGING TOOLS AND TECHNOLOGIES (U01)

NIH: National Institute of Biomedical Imaging and Bioengineering

*** The closing date for this opportunity has been extended. The previous deadline of 20 January has been extended to 1 February 2017. All other call details remain unchanged. This call supports full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. ***

Closing date: 01 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-17-002.html

SHORT-TERM MEASUREMENTS OF PHYSICAL RESILIENCE AS A PREDICTOR OF HEALTHSPAN IN MICE (R01)

NIH: National Institute on Aging

This aims to develop short-term tests that provide a comprehensive measure of resilience in animal models used in ageing studies. Application budgets are worth up to USD 250,000 in direct costs per year for a maximum period of five years.

Closing date: 02 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-040.html

EXOSOMES: FROM BIOGENESIS AND SECRETION TO THE EARLY PATHOGENESIS OF ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This seeks innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimer's disease. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 03 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-051.html

ENHANCING THE TARGET AND BIOMARKER DISCOVERY EFFORTS OF THE AMP-AD AND M2OVE-AD CONSORTIA (R01)

NIH: National Institute on Aging

This supports applications that enhance the goals and deliverables of the AMP-AD target discovery and preclinical validation and M2OVE consortia by maximising the usability of the data and analytical results generated by these programmes, seizing opportunities for additional target and biomarker discovery, and accelerating the validation of the novel targets and biomarkers being discovered within the AMP-AD and M2OVE-AD consortia. Application budgets are worth up to USD 750,000 per year for a maximum period of three years.

Closing date: 03 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-054.html

PRAGMATIC TRIALS FOR DEMENTIA CARE IN LONG-TERM SERVICES AND SUPPORT SETTINGS (R21/R33)

NIH: National Institute on Aging

This supports trials for dementia care that are designed to address practical comparative questions faced by Alzheimer's disease and related dementia patients, clinicians, and caregivers, include broad and diverse populations and be conducted in real-world settings. The total budget is worth USD 12.8 million to fund up to 10 awards. Application budgets for the R21 planning phase are worth USD 400,000 for a two-year period. For the R33 phase, budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 03 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-065.html

PRAGMATIC TRIALS FOR DEMENTIA CARE IN LONG-TERM SERVICES AND SUPPORT SETTINGS (R01)

NIH: National Institute on Aging

This supports trials for dementia care that are designed to address practical comparative questions faced by Alzheimer's disease and related dementia patients, clinicians, and caregivers, include broad and diverse populations and be conducted in real-world settings. The total budget is worth USD 3 million to fund three to four awards in fiscal year 2017. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 03 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-064.html

DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01)

NIH: National Institute of Mental Health

This supports research that will identify, develop, test, evaluate or refine strategies to disseminate and implement evidence-based practices, such as behavioural interventions, prevention, early detection, diagnostic, treatment and disease management interventions, quality improvement programmes, into public health, clinical practice, and community settings. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-238.html

GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Application budgets are not limited, but should reflect the needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-110.html

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-261.html

PRESCRIPTION DRUG ABUSE (R01)

NIH: National Institute on Drug Abuse

This announcement aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug

abuse; to characterise the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-233.html

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement supports rigourous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. Application budgets are not limited but should reflect the actual costs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-251.html

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01)

NIH: National Institute on Drug Abuse

This announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-142.html

BIOENGINEERING RESEARCH GRANTS (R01)

NIH: National Institute of Biomedical Imaging and Bioengineering

These aim to foster the development of an innovative technology, model, technique, design or method that has the potential for significant impact on biomedical research by infusing principles and concepts from the quantitative sciences. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum award period is 5 years depending on the policy of each NIH Institute.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-242.html

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R01)

NIH: National Institute on Drug Abuse

This aims to encourage behavioural intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations and ascertain best sequencing of behavioural, combined, sequential or integrated behavioural and pharmacological drug abuse treatment and interventions. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-072.html

OCCUPATIONAL SAFETY AND HEALTH RESEARCH (R01)

Centers for Disease Control and Prevention (CDC)

The purpose of this R01 funding opportunity announcement is to develop an understanding of the risks and conditions associated with occupational diseases and injuries. Applicants may request a budget for direct costs of up to US$400,000 per year for up to four years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-13-129.html

MODELLING OF INFECTIOUS DISEASE AGENT STUDY RESEARCH PROJECTS (R01)

NIH: National Institute of General Medical Sciences

This U01 funding opportunity announcement provides the US scientific and public health communities better resources, knowledge and tools to improve their ability to identify and prevent the spread of infectious diseases.

Direct costs may not exceed US$500,000 per year for a maximum of five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-107.html

ADVANCING ERYTHROID CELL BIOLOGY (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This R01 funding opportunity announcement supports research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components contribute to erythropoiesis. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-039.html

LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH REGULAR RESEARCH PROGRAMME (R01)

NIH: National Human Genome Research Institute

The purpose of this is to study the ethical, legal and social implications of human genome research. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years, however many projects that are funded will be no more than three years in duration.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-276.html

ANCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement funds ancillary studies to major ongoing research studies, including clinical trials and prospective observational studies. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-034.html

ADDRESSING HEALTH DISPARITIES IN NIDDK DISEASES (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This aims to improve understanding of the causes of high priority diseases in the US and reducing and eliminating health disparities. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-021.html

MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01)

NIH: National Cancer Institute

This announcement aims to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and aims to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these institutes and centres. Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-188.html

RESEARCH PROJECT GRANT (PARENT R01)

NIH: National Institutes of Health

This announcement supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigators. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-160.html

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01)

NIH: National Institute on Drug Abuse

This intends to stimulate model driven research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum funding period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-061.html

BIOLOGY OF MANUAL THERAPIES (R01)

NIH: National Center for Complementary and Integrative Health

This supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-168.html

NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-13-359.html

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-295.html

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01)

NIH: National Institute of Nursing Research

This call aims to enhance our understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males across the life cycle, and encourage applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males age 18 and older. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-428.html

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This aims to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms and alcohol use disorders.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-190.html

INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01)

NIH: National Institute on Alcohol Abuse and Alcoholism

The purpose is to foster international collaborations between alcohol research investigators within the US and investigators located at non-US laboratories and performance sites, for the mutual advancement of the understanding of alcohol problems and of clinical and public health approaches to their solutions. Grants are worth up to US$250,000 per year for direct costs. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-268.html

PROGRAMME FOR EXTRAMURAL OR INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages collaboration between alcohol researchers in the extramural community and those within the NIAAA intramural research programme. Applicants may request direct costs of up to US$250,000 per year. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-214.html

NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01)

NIH: National Library of Medicine

This announcement offers support for innovative research in biomedical informatics and data science. Grants are worth up to USD 250,000 per year each for up to four years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-404.html

EPIDEMIOLOGY OF DRUG ABUSE (R01)

NIH: National Institute on Drug Abuse

These support projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities and diverse population groups. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-003.html

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

These support investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-338.html

INVESTIGATIONS ON PRIMARY IMMUNODEFICIENCY DISEASES (R01)

NIH: National Institute of Allergy and Infectious Diseases

This announcement supports innovative investigations in primary immunodeficiency diseases. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-130.html

DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01)

NIH: National Institute on Drug Abuse

This announcement aims to support research that will employ rigourous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-082.html

METHODOLOGY AND MEASUREMENT IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01)

NIH: Office of the Director

This supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-260.html

QUANTITATIVE IMAGING FOR EVALUATION OF RESPONSES TO CANCER THERAPIES (U01)

NIH: National Cancer Institute

This aims to enhance the value of quantitative imaging in clinical trials for prediction or measurement of response to cancer therapies. Applicants may request direct costs of up to US$500,000 per year, over a maximum five-year project period.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-116.html

RESEARCH TO ADVANCE VACCINE SAFETY (R01)

NIH: National Institute of Allergy and Infectious Diseases

This announcement supports research that will contribute to the overall understanding of vaccine safety. Budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-312.html

DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01)

NIH: National Institute of Mental Health

This announcement aims to stimulate the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-041.html

ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01)

NIH: National Institute on Drug Abuse

This call supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the etiology and epidemiology of drug-using behaviours and related disorders, prevention of drug use and HIV, and health service use. Direct costs are limited to US$500,000 per year for up to five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-234.html

OBESITY POLICY EVALUATION RESEARCH (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement encourages evaluations of large scale policies or programmes that are expected to influence obesity-related behaviours or weight outcomes in an effort to prevent or reduce obesity. Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-165.html

SELECTED TOPICS IN TRANSFUSION MEDICINE (R01)

NIH: National Heart, Lung and Blood Institute

This encourages applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-440.html

STIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement aims to promote innovative, high quality haematology research relevant to the mission of the NIDDK. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAS-16-033.html

ADVANCES IN POLYCYSTIC KIDNEY DISEASE (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement aims to increase investigator interest in basic and applied investigations of the etiology and pathogenesis of polycystic kidney disease, in both its autosomal dominant and autosomal recessive forms. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-159.html

MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-102.html

RESEARCH ON AUTISM SPECTRUM DISORDERS (R01)

NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to ASD. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-388.html

NATURAL HISTORY OF DISORDERS IDENTIFIABLE BY NEWBORN SCREENING (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement aims to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-061.html

HIV INCIDENCE ASSAYS WITH IMPROVED SPECIFICITY (R01)

NIH: National Institute of Allergy and Infectious Diseases

This announcement supports projects that seek to develop novel biomarkers and improved HIV incidence assays and algorithms, with increased specificity for distinguishing incident from chronic HIV infections. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-105.html

RESEARCH ON HEARING HEALTHCARE (R01)

NIH: National Institute on Deafness and other Communication Disorders

This R01 funding opportunity announcement supports research leading to accessible and affordable hearing healthcare. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-091.html

NEUROBIOLOGY OF MIGRAINE (R01)

NIH: National Institute of Neurological Disorders and Stroke

These R01 grants support research elucidating the mechanisms underlying migraine, expanding our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression, and exploring new therapeutic targets and therapies for acute migraine management and longer term prevention. Applicants may request support for up to five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-068.html

PRECLINICAL RESEARCH ON MODEL ORGANISMS TO PREDICT TREATMENT OUTCOMES FOR DISORDERS ASSOCIATED WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages preclinical research in model organisms of neurodevelopmental disorders. Application budgets are limited to US$499,999 per year over a period of up to five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-215.html

OUTCOME MEASURES FOR USE IN TREATMENT TRIALS FOR INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement aims to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities. Application budgets are limited to US$499,999 per year over a five-year period.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-216.html

ANCILLARY STUDIES TO THE NIDDK INTESTINAL STEM CELL CONSORTIUM (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement seeks applications to conduct ancillary studies to the NIDDK intestinal stem cell consortium. Application budgets are not limited but should reflect actual needs of the proposed projects. The maximum period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-062.html

FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01)

NIH: National Institute on Aging

This R01 funding opportunity announcement encourages innovative, hypothesis-driven research that can expand understanding of the role and impact of families and interpersonal relationships on health and well-being in midlife and older age. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-042.html

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

These R01 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation. Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html

SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01)

NIH: National Cancer Institute

This R01 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-010.html

OBESITY AND ASTHMA: AWARENESS AND SELF-MANAGEMENT (R01)

NIH: National Institute of Nursing Research

The purpose of this R01 funding opportunity announcement is to stimulate research to examine the relationship between asthma, obesity and self-management. Application budgets are not limited, but should reflect the actual needs of the project. The maximum period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-316.html

MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R01 funding opportunity announcement supports research in the mechanistic studies on the relationship between excessive alcohol drinking, alcohol dependence and pain with the aim of understanding genetic, pharmacological and learning mechanisms underlying the association between the propensity to drink alcohol excessively and pain responses. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://www.grants.nih.gov/grants/guide/pa-files/PA-15-026.html

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01)

NIH: National Institute of Mental Health

This R01 funding opportunity announcement encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. Application budgets are not limited but must reflect the actual needs of the proposed project.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-309.html

SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01)

NIH: Office of the Director

This R01 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-048.html

BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01)

NIH: National Institute of Dental and Craniofacial Research

This R01 funding opportunity announcement encourages research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which there is no strong understanding of the genetics or genomics of the disease or disorder. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html

BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01)

NIH: National Institute of Mental Health

This announcement encourages research to develop novel, robust assays to reveal changes in neuronal and glial function. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is four years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-066.html

HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01)

NIH: National Institute of Nursing Research

This R01 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-177.html

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01)

NIH: National Institute of Nursing Research

The purpose of this R01 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. Application budgets are not limited, but need to reflect actual needs of the proposed project.

The total project period is a maximum of five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-180.html

ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function, with the goal of improving the outcome of patients who abuse alcohol. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-159.html

MECHANISMS MEDIATING OSTEOARTHRITIS IN AGEING (R01)

NIH: National Institute on Aging

This announcement encourages and accelerates the characterisation of new or underutilised models and the testing of hypotheses that will lead to an improved understanding of the mechanisms mediating osteoarthritic progression. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-239.html

DISCOVERY OF IN VIVO CHEMICAL PROBES (R01)

NIH: National Institute of Mental Health

This R01 funding opportunity supports research in the following fields: discovery and development of novel, small molecules for their potential use in studying disease treatment, relevant to the missions of the participating NIH institutes; discovery or validation of novel, biological targets that will inform studies of disease mechanisms. Application budgets are not limited but need to reflect the actual needs of the proposed project. Projects may not exceed three years in length.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-279.html

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01)

NIH: National Institute of Mental Health

This R01 funding opportunity announcement encourages investigators to form collaborations with an established academic, non-profit or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed three years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-284.html

MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01)

NIH: National Institute of Nursing Research

This announcement encourages projects to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-100.html

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01)

NIH: National Institute of Nursing Research

This R01 funding opportunity announcement encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities in non-traditional settings where exposure to environmental pollutants and toxins may occur. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-263.html

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01)

NIH: National Cancer Institute

This announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-122.html

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R01 announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-058.html

CLINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01)

NIH: National Institute on Drug Abuse

This funding opportunity announcement solicits proposals that seek to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. Application budgets are limited to US$275,000 over a two-year period with no more than US$200,000 in either year.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-075.html

LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This R01 funding opportunity announcement supports research into aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of digestive system, kidney and urinary tract organs. Application budgets are limited to US$250,000 in direct costs per year. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-306.html#_Section_III._Eligibility

EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01)

NIH: National Cancer Institute

This announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-012.html

IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R01)

NIH: Office of the Director

This R01 funding opportunity announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. Application budgets are not limited, but must reflect the actual needs of the proposed project. The maximum project period is five year.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-093.html

EARLY-STAGE PRECLINICAL VALIDATION OF THERAPEUTIC LEADS FOR DISEASES OF INTEREST TO THE NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement aims to stimulate research and technology development to promote the early-stage preclinical validation of therapeutic leads such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-121.html

EXTENDED DEADLINE: ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01)

NIH: National Institute on Aging

*** The National Institute on Aging, the National Institute of Nursing Research, the National Center for Complementary and integrative Health and the National Cancer Institute extends the expiration date for their advancing the science of geriatric palliative care (R01) funding opportunity announcement. The previous expiration date of 8 January 2017 has been extended to 8 May 2017. All other call information remain unchanged. This announcement encourages research grant applications focused on palliative care in geriatric populations. The maximum project period is five years. ***

Closing date: 05 Feb 17
Website:

http://grants.nih.gov/grants/guide/pa-files/PA-13-354.html

PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01)

NIH: National Institute on Drug Abuse

This R01 funding opportunity announcement encourages research on the impact of changing marijuana policies and laws on public health outcomes. Application budgets are not limited but must reflect the actual needs of the project. The maximum project

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAS-14-020.html

NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01)

NIH: National Institute on Drug Abuse

This R01 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-084.html

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01)

NIH: National Institute on Drug Abuse

This R01 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-106.html

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01)

NIH: National Institute of Nursing Research

This R01 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-112.html

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R01 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-123.html

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01)

NIH: National Institute on Drug Abuse

This R01 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing

infections more effectively. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-137.html

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R01 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-139.html

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01)

NIH: National Institute of Nursing Research

This R01 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes. Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-142.html

ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01)

NIH: National Institute of Dental and Craniofacial Research

This R01 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social

contributors to dental, oral or craniofacial diseases. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-143.html

EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01)

NIH: National Institute of General Medical Sciences

This R01 funding opportunity announcement aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Application budgets may not exceed US$300,000 direct costs per year, over a maximum project period of three years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-155.html

EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01)

NIH: National Institute of General Medical Sciences

This R01 funding opportunity announcement supports the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-156.html

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01)

NIH: National Institute on Aging

This R01 funding opportunity announcement supports translational research collaborations to develop tools, techniques, programmes or policies to respond to the needs of the ageing

population. Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-161.html

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01)

NIH: National Institute on Drug Abuse

This R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-163.html

CLINICAL STUDIES OF MENTAL ILLNESS NOT INVOLVING TREATMENT DEVELOPMENT, EFFICACY OR EFFECTIVENESS TRIALS (COLLABORATIVE R01)

NIH: National Institute of Mental Health

This collaborative R01 funding opportunity announcement seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-165.html

NIH STROKENET CLINICAL TRIALS AND BIOMARKER STUDIES FOR STROKE TREATMENT, RECOVERY AND PREVENTION (U01)

NIH: National Institutes of Health

This U01 funding announcement encourages multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome

measure validation studies that are immediately preparatory to trails in stroke prevention, treatment and recovery. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-220.html

CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01)

NIH: National Institute on Drug Abuse

The purpose of this R01 funding opportunity is to support meritorious clinical studies that seek to characterise opioid and pharmaceutical adjunct combinations that safely improve analgesia in chronic pain patients. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is three years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-225.html

ADVANCING RESEARCH IN VOICE DISORDERS (R01)

NIH: National Institute on Deafness and other Communication Disorders

The purpose of this R01 funding opportunity is focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-236.html

COLLABORATIVE RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MAMMALIAN MODELS FOR TRANSLATIONAL RESEARCH (COLLABORATIVE R01)

NIH: National Cancer Institute

This funding opportunity aims to support collaborative R01 projects from multidisciplinary teams to expand, improve, or transform the utility of mammalian cancer and tumour models for translational research. Application budgets are limited to US$450,000 direct costs per year. The maximum project period is three years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-058.html

RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MAMMALIAN MODELS FOR TRANSLATIONAL RESEARCH (R01)

NIH: National Cancer Institute

This announcement aims to support projects that expand and improve the utility of mammalian cancer and tumour models for translational research. Application budgets are limited to US$450,000 direct costs per year. The maximum project period is three years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-059.html

RESEARCH ON CHRONIC OVERLAPPING PAIN CONDITIONS (R01)

NIH: National Institutes of Health

The purpose of this R01 funding opportunity is to encourage epidemiological, clinical and translational research that will increase our understanding of the risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-244.html

ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01)

NIH: National Center for Complementary and Integrative Health

The purpose of this R01 funding opportunity announcement is to foster research on the potential for arts-based approaches to enhance palliative care for individuals living with multiple symptoms related to serious chronic or terminal illness. Applicants may request up to US$300,000 in direct costs per year. The maximum project period is three years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-294.html

UNDERSTANDING FACTORS IN INFANCY AND EARLY CHILDHOOD THAT INFLUENCE OBESITY DEVELOPMENT (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement seeks applications that propose to characterize or identify factors in early childhood that may increase or mitigate risk for obesity or excessive weight gain or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-169.html

SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01)

NIH: National Institute of Nursing Research

These R01 grants support activities that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses and conditions. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-344.html

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01)

NIH: National Institute of Dental and Craniofacial Research

This R01 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Budgets are not limited but must reflect the actual needs of the proposed project.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-358.html

BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01)

NIH: National Institutes of Health

These R01 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Grants are awarded for a maximum project period of five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-017.html

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01)

NIH: National Institute of Neurological Disorders and Stroke

These R01 grants aim to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAS-15-029.html

RESEARCH ON EOSINOPHIL ASSOCIATED DISORDERS (R01)

NIH: National Institute of Allergy and Infectious Diseases

These R01 grants encourage research aimed at elucidating the pathophysiology of eosinophil-associated disorders and clarifying the cellular and molecular mechanisms underlying the role of eosinophil leukocytes in these condition. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-027.html

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01)

NIH: National Institute on Aging

This announcement encourages basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-037.html

NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01)

NIH: National Institute of Dental and Craniofacial Research

This U01 announcement supports investigator-initiated phase I, II, III or IV clinical trials, stage one to four behavioural or social intervention trials or biomarker validation studies that require prospective collection of clinical outcomes and clinical specimens through the funding mechanism. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-059.html

ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01)

NIH: National Cancer Institute

This announcement enables academic and industrial investigators to form research partnerships and work together to solve a targeted cancer problem. Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-075.html

PREVENTION RESEARCH IN MID-LIFE ADULTS (R01)

NIH: National Institute of Nursing Research

This announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-098.html

ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01)

NIH: National Cancer Institute

This announcement supports interdisciplinary collaborations across scientific disciplines engaged in microbiome and probiotic or prebiotic research. Application budgets must reflect the actual needs of the proposed projects. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-127.html

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01)

NIH: National Cancer Institute

This announcement stimulates research focused on the role of early-life factors in cancer development in later life. Application budgets need to reflect the actual needs of the proposed projects. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-126.html

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R01)

NIH: National Institutes of Health

This announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-133.html

IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01)

NIH: National Institute of Dental and Craniofacial Research

This announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-192.html

DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01)

NIH: National Institute on Drug Abuse

This announcement supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is four years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-188.html

STUDIES AT PERIVIABLE GESTATION (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-200.html

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://www.grants.nih.gov/grants/guide/pa-files/PA-15-256.html

BIOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Funding enables bioengineering and biomedical scientists to collaborate in developing non- and minimally-invasive methods for measuring biochemical substances in connection with the care of perinatal patient populations. Application budgets must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-285.html

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01)

NIH: National Institute of Nursing Research

This announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-324.html

RESEARCH ON THE MECHANISMS OR BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01)

NIH: National Institutes of Health

This announcement supports basic, behavioural and clinical research projects examining the interactions between neural systems such as cognitive, affective or motor processes and multiple sensory modalitites. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html

PHASE III CLINICAL TRIALS FOR THE SPECTRUM OF ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE (R01)

NIH: National Institute on Aging

This announcement supports the development and implementation of phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease spectrum from pre-symptomatic to more severe stages of disease. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-364.html

PILOT CLINICAL TRIALS FOR THE SPECTRUM OF ALZHEIMER'S DISEASE AND AGE-RELATED COGNITIVE DECLINE (R01)

NIH: National Institute on Aging

This announcement supports the development and implementation of phase I or II clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and individuals with Alzheimer's disease across the spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance trial design and methods. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-365.html

EMERGING DIRECTIONS FOR ADDRESSING HEALTH DISPARITIES IN ALZHEIMER'S DISEASE (R03)

NIH: National Institute on Aging

These support health disparities research related to Alzheimer's disease, including the study of biological, behavioural, sociocultural and environmental factors that influence population level health differences. The initiative intends to commit a total estimated budget of US$2 million in fiscal year 2016 to fund 15 to 20 awards. Budgets are limited to US$50,000 in direct costs per year. The maximum project period is two years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-350.html

RESEARCH ON INFORMAL AND FORMAL CAREGIVING FOR ALZHEIMER'S DISEASE (R21)

NIH: National Institute on Aging

This call supports basic and translational research on caregiving for individuals with Alzheimer's disease, at the individual, family, community and population level. NIH intends to commit a total of US$3 million to fund an estimate of 10 to 12 awards for fiscal year 2016. Direct costs are limited to US$275,000 over the two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-351.html

HEALTH DISPARITIES AND ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

These support health-disparities research related to Alzheimer's disease, including the study of biological, behavioural, sociocultural, and environmental factors that influence population level health differences. The initiative intends to commit a total estimated budget of US$10 million in fiscal year 2016 to fund 10 to 12 awards. Budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-349.html

MAJOR OPPORTUNITIES FOR RESEARCH IN EPIDEMIOLOGY OF ALZHEIMER'S DISEASE AND COGNITIVE RESILIENCE (R01)

NIH: National Institute on Aging

This encourages investigator-initiated applications addressing the epidemiology of Alzheimer's disease, as well as protective factors for cognitive health and resilience. NIH intends to commit a total of US$12 million to fund an estimate of 10 to 15 awards for fiscal year 2016. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/notice-files/NOT-AG-16-005.html

RESEARCH ON INFORMAL AND FORMAL CAREGIVING FOR ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

Research proposals may address the following: interventions to reduce caregiver burden and improve patient outcomes across various settings; population- and community-based research on the scope and impact of AD caregiving; improved characterisation of informal and formal caregiving and the burden of caregiving across the full spectrum of the disease, including differences among socio-economic, racial or ethnic and geographic sub-populations; research addressing the unique challenges related to the provision of advanced AD care, including disparities in access to care. The initiative intends to commit a total estimated budget of US$10 million in fiscal year 2016 to fund 12 to 16 awards. Budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-348.html

UNDERSTANDING ALZHEIMER'S DISEASE IN THE CONTEXT OF THE AGEING BRAIN (R01)

NIH: National Institute on Aging

This announcement encourages research that aims to establish the role and impact of brain ageing in the development and progression of Alzheimer's disease. NIA intends to commit a total of US$10 million to fund approximately 20 to 25 awards for fiscal year 2016.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/notice-files/NOT-AG-16-006.html

CAPTURING COMPLEXITY IN THE MOLECULAR AND CELLULAR MECHANISMS INVOLVED IN THE AETIOLOGY OF ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This announcement aims to support innovative research focused on understanding the molecular and cellular mechanisms underlying the heterogeneity and multi-factorial nature of Alzheimer's disease with the potential to create new or challenge existing scientific paradigms. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-358.html

NOVEL APPROACHES TO DIAGNOSING ALZHEIMER'S DISEASE AND PREDICTING PROGRESSION (R01)

NIH: National Institute on Aging

This announcement aims to identify novel biomarkers to diagnose Alzheimer's disease and to predict clinical course. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-359.html

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01)

NIH: National Institute of Nursing Research

This announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-007.html

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01)

NIH: National Institute of Nursing Research

This announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified innovative questions in symptom and genomic nursing science. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-024.html

APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R01)

NIH: National Institute of Nursing Research

This announcement encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-030.html

ADVANCING UNDERSTANDING, PREVENTION AND MANAGEMENT OF INFECTIONS TRANSMITTED FROM WOMEN TO THEIR INFANTS (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will increase scientific understanding of and treatments for high-priority perinatal infections. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-032.html

ANCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within its mission by leveraging ongoing large, multi-centre clinical research studies through ancillary studies. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-034.html

IMPROVING OUTCOMES IN CANCER TREATMENT-RELATED CARDIOTOXICITY (R01)

NIH: National Cancer Institute

This announcement supports a collaborative project that will contribute to the identification and characterisation of patients at risk of developing cancer treatment-related cardiotoxicity. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-035.html

CLINICAL DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01)

NIH: National Institute on Drug Abuse

This announcement encourages applications that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. Application budgets are limited to US$500,000 per year over the maximum project period of three years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-076.html

EDUCATION AND HEALTH: NEW FRONTIERS (R01)

NIH: National Institutes of Health

This announcement aims to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the casual relationship. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-080.html

OOCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-088.html

ACCELERATING RESEARCH ON INTERVERTEBRAL DISC (R01)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This announcement encourages studies on basic biology of the intervertebral disc and seeks applications that accelerate an understanding of basic research on the intervertebral disc and develop new directions on the factors that lead to disc degeneration. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-097.html

USING THE NIMH RESEARCH DOMAIN CRITERIA APPROACH TO UNDERSTAND PSYCHOSIS (R01)

NIH: National Institute of Mental Health

This announcement seeks applications which propose research studies that will use the NIMH's research domain criteria framework to advance scientific understanding of neurobehavioral mechanisms related to psychotic symptoms such as hallucinations, delusions, disorganised behaviour, and thought disorder. Application budgets are limited to US$500,000 in annual direct costs for the maximum period of five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-136.html

ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R01)

NIH: National Institute on Drug Abuse

This announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-144.html

POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R01)

NIH: Office of the Director

This announcement supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-146.html

DIET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement aims to enhance the quality of measurements of dietary intake and physical activity. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-167.html

ROLE OF MOBILE GENETIC ELEMENTS IN CANCER (R01)

NIH: National Institutes of Health

This R01 funding opportunity announcement aims to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-227.html

METABOLIC REPROGRAMMING TO IMPROVE IMMUNOTHERAPY (R01)

NIH: National Cancer Institute

This announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the tumour, the immune response, or both to improve cancer immunotherapy.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-228.html

NON-HEALING ULCERATIVE WOUNDS IN AGEING (R01)

NIH: National Institute on Aging

This announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-230.html

NOVEL APPROACHES TO UNDERSTANDING, PREVENTING AND TREATING LYME DISEASE AND TICK-BORNE COINFECTIONS (R01)

NIH: National Institute of Allergy and Infectious Diseases

This R01 funding opportunity announcement supports research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by Ixodes ticks. Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Closing date: 05 Feb 17

Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-243.html

GENE FUSION IN PAEDIATRIC SARCOMAS (R01)

NIH: National Cancer Institute

This R01 funding opportunity announcement encourages applications that explore the molecular biology of paediatric sarcomas to elucidate molecular mechanisms by which fusion genes and the resulting protein products drive tumorigenesis and cancer progression. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17

Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-251.html

DEVELOPMENT AND APPLICATION OF POSITRON EMISSION TOMOGRAPHY AND SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND PATHOPHYSIOLOGICAL STUDIES OF CENTRAL NERVOUS SYSTEM DISORDERS (R01)

NIH: National Institute of Mental Health

This R01 funding opportunity announcement encourages development of PET and SPECT probes for molecular targets, such as receptors, intracellular messengers, disease-related proteins, that are implicated in mental disorders, drug and alcohol abuse, and nervous system disorders associated with ageing or as tools to study disease pathophysiology for assessing target engagement of potential therapeutic candidates. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is three years.

Closing date: 05 Feb 17

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-16-266.html#_3._Additional_Information

FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R01)

NIH: National Institute of Dental and Craniofacial Research

This supports research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-295.html

CHARACTERISATION OF THE ADOLESCENT REPRODUCTIVE TRANSITION (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports outstanding research in the area of puberty and the trajectory of sexual development and research using new technologies and approaches to fill knowledge gaps and advance understanding of normative sexual development in both males and females. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-314.html

SAFETY AND OUTCOME MEASURES OF PAIN MEDICATIONS USED IN CHILDREN AND PREGNANT WOMEN (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations and develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-311.html

METABOLIC CONTRIBUTIONS TO THE NEUROCOGNITIVE COMPLICATIONS OF DIABETES: ANCILLARY STUDIES (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports human studies aiming to elucidate the aetiology and pathogenesis of the increased risk for neurocognitive impairment associated with type two diabetes. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:

PHENOTYPIC AND FUNCTIONAL CHARACTERISATION OF APOLIPOPROTEIN E TWO TO INFORM TRANSLATION STRATEGIES FOR AGING-RELATED CONDITIONS (R01)

NIH: National Institute on Aging

This supports basic and translational studies on ApoE2 and other variants to improve understanding of physiologic and cellular differences attributable to the ApoE e2 allele, versus other ApoE alleles, and how they mediate ApoE e2's differential effects on longevity and risk for age-related conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-370.html

ASSAY DEVELOPMENT AND SCREENING TO DISCOVER THERAPEUTIC OR IMAGING AGENTS FOR DISEASES OF INTEREST TO THE NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This aims to develop, validate, or conduct a screen using a novel assay to identify therapeutic or imaging agents relevant to health related outcomes of interest to the NIDDK. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-374.html

ENGINEERING NEXT-GENERATION HUMAN NERVOUS SYSTEM MICROPHYSIOLOGICAL SYSTEMS (R01)

NIH: National Institute of Mental Health

This announcement aims to stimulate basic research to develop next-generation human cell-derived microphysiological systems with improved fidelity to complex human brain, spinal, peripheral nervous system and sensory end organ circuit physiology in vivo. Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-398.html

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project duration is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-395.html

SYMPTOM MANAGEMENT IN HIV-INFECTED INDIVIDUALS WITH COMORBID CONDITIONS (R01)

NIH: National Institute of Nursing Research

This call seeks research applications focused on developing, adapting and testing innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated non-AIDS conditions and other comorbidities among older adults with prolonged HIV infection. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-427.html

BASIC AND TRANSLATIONAL RESEARCH ON DECISION MAKING IN AGEING AND ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This seeks applications for basic research to better characterise the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal ageing and Alzheimer's disease. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-448.html

TROPHOBLAST DIFFERENTIATION AND FUNCTION (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages applications from the scientific community to support outstanding research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-445.html

PALLIATIVE CARE NEEDS OF INDIVIDUALS WITH RARE ADVANCED DISEASES AND THEIR FAMILY CAREGIVERS (R01)

NIH: National Institute of Nursing Research

This aims to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-018.html

IMPROVING INDIVIDUAL AND FAMILY OUTCOMES THROUGH CONTINUITY AND CO-ORDINATION OF CARE IN HOSPICE (R01)

NIH: National Institute of Nursing Research

This seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimising the individual and family outcomes related to high quality co-ordination of care of individuals who are enrolled in hospice. Applications budgets are not limited but need to reflect the actual need of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-016.html

ADDRESSING UNMET NEEDS IN PERSONS WITH DEMENTIA TO DECREASE BEHAVIOURAL SYMPTOMS AND IMPROVE QUALITY OF LIFE (R01)

NIH: National Institute of Nursing Research

This aims to stimulate clinical research addressing behavioural and psychological symptoms of dementia and the association of BPSD with unmet physical, social or environmental needs in persons with dementia. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-014.html

SELF-MANAGEMENT INTERVENTIONS AND TECHNOLOGIES TO SUSTAIN HEALTH AND OPTIMISE FUNCTIONAL CAPABILITIES (R01)

NIH: National Institute of Nursing Research

This seeks clinical research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimise and maintain existing functional capabilities, prevent or delay disabilities and navigate their environment. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-012.html

USE OF TECHNOLOGY TO ENHANCE PATIENT OUTCOMES AND PREVENT ILLNESS (R01)

NIH: National Institute of Nursing Research

This seeks clinical research focused on the development and utilisation of technologies that can help address patient outcomes. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-010.html

COMMON MECHANISMS AND INTERACTIONS AMONG NEURODEGENERATIVE DISEASES (R01)

NIH: National Institute on Aging

This encourages preclinical and clinical research to study whether, and how, different neurodegenerative disease processes interact with one another to initiate and hasten progression of neuropathology and dementia. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAS-17-028.html

IMPROVING QUALITY OF CARE AND QUALITY OF LIFE FOR PERSONS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS AT THE END OF LIFE (R01)

NIH: National Institute on Aging

This seeks applications that address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimer's disease and related dementias and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAS-17-027.html

DYNAMIC INTERACTIONS BETWEEN SYSTEMIC OR NON-NEURONAL SYSTEMS AND THE BRAIN IN AGEING AND IN ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This supports research projects on the role of ageing-related changes in systemic, peripheral, and non-neuronal factors individually or in combination to the pathogenesis, presentation, and progression of Alzheimer's disease.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-029.html

INTEGRATIVE RESEARCH TO UNDERSTAND THE IMPACT OF SEX DIFFERENCES ON THE MOLECULAR DETERMINANTS OF ALZHEIMER'S DISEASE RISK AND RESPONSIVENESS TO TREATMENT (R01)

NIH: National Institute on Aging

This seeks applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain ageing and phenotypes of Alzheimer's disease risk and on the responsiveness to pharmacologic and non-pharmacologic interventions. Application budgets are worth up to USD 750,000 per year for a maximum period of five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-033.html

TRANSLATIONAL BIOINFORMATICS APPROACHES TO ADVANCE DRUG REPOSITIONING AND COMBINATION THERAPY DEVELOPMENT FOR ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This seeks applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias with proof-of-concept efficacy studies in cell-based models, animal models and humans. Application budgets are worth up to USD 500,000 per year for maximum period of five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-032.html

ROLE OF AGE-ASSOCIATED METABOLIC CHANGES IN ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This seeks innovative experimental approaches to explore the molecular and cellular bases for age-related change in metabolism that impact the development of Alzheimer's disease. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-031.html

CLARIFIYING THE RELATIONSHIP BETWEEN DELIRIUM AND ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (R01)

NIH: National Institute on Aging

This aims to clarify the relationship between delirium and Alzheimer's disease and related dementias. Award applications are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-038.html

SELECTIVE CELL AND NETWORK VULNERABILITY IN AGEING AND ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This aims to define and characterise neural cell populations, neural circuits and brain networks and regions that are vulnerable to brain ageing and Alzheimer's disease. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-047.html

LEVERAGING EXISTING COHORT STUDIES TO CLARIFY RISK AND PROTECTIVE FACTORS FOR ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (R01)

NIH: National Institute on Aging

This supports applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias. The total budget is worth USD 8 million to fund five to eight awards in fiscal year 2017. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-054.html

ORAL ANTICANCER AGENTS: UTILISATION, ADHERENCE AND HEALTH CARE DELIVERY (R01)

NIH: National Cancer Institute

This aims to assess and describe the current state of oral anticancer medication utilisation, delivery and adherence, identify structural, systemic, and psychosocial barriers to adherence and develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimised. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-060.html

BASIC MECHANISMS OF BRAIN DEVELOPMENT MEDIATING SUBSTANCE USE AND DEPENDENCE (R01)

NIH: National Institute on Drug Abuse

This supports applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behaviour and in substance use and dependence. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is five years.

Closing date: 05 Feb 17
Website:
https://grants.nih.gov/grants/guide/pa-files/PA-17-119.html

CANCER-RELATED BEHAVIOURAL RESEARCH THROUGH INTEGRATING EXISTING DATA (R01)

NIH: National Cancer Institute

This announcement supports research that integrates two or more independent data sets to answer novel cancer control and prevention questions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Closing date: 07 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-256.html

NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01)

NIH: National Institute of Neurological Disorders and Stroke

The purpose of this U01 funding opportunity announcement is the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets will normally remain under US$500,000 in direct costs in any given year. The project period is typically three years and may not exceed four years.

Closing date: 08 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-286.html

NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

The purpose of this UH2/UH3 funding opportunity announcement is the development of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. Applications should rarely exceed US$1million in direct costs per year during the UH2 phase and US$1.5million in direct costs per year during the UH3 phase. The proposed project period for the UH2 phase may not exceed two years and the UH3 phase may not exceed four and a half years. The total duration of UH2 and UH3 phases may not exceed five years.

Closing date: 08 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-288.html

BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

The purpose of this UH2/UH3 funding opportunity announcement is to help neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined duration of the UH2 and UH3 award cannot exceed five years.

Closing date: 08 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html

NIDCD PHASE III CLINICAL TRIALS IN COMMUNICATION DISORDERS (U34)

NIH: National Institute on Deafness and other Communication Disorders

This announcement supports a cooperative agreement between an NIDCD Project Scientist and investigator to support phase I and II clinical trials of preliminary efficacy and phase III clinical trials of definitive efficacy. Application budgets are not limited, but must reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 09 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-116.html

NIDCD PLANNING GRANT FOR PHASE III CLINICAL TRIALS IN COMMUNICATION DISORDERS (U34)

NIH: National Institute on Deafness and other Communication Disorders

This announcement supports a cooperative agreement between NIDCD project scientist and investigator for a planning grant for phase III clinical trials of definitive efficacy. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year.

Closing date: 09 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-117.html

EARLY PHASE CLINICAL TRIALS IN IMAGING AND IMAGE-GUIDED INTERVENTIONS (R01)

NIH: National Cancer Institute

This R01 funding opportunity announcement supports clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modelling, 3D reconstruction and other quantitative tools. Direct costs are limited to US$500,000 over a three-year period, with no more than US$250,000 in direct costs allowed in any single year.

Closing date: 09 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-166.html

BRAIN LYMPHATIC SYSTEM IN AGEING AND ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This supports research that will lead to a greater understanding of complex mechanisms by which the brain glymphatic system and meningeal and peripheral lymphatic systems change in normal and pathological brains. Application budgets are worth up to USD 500,000 each in direct costs per year for a maximum period of five years.

Closing date: 09 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-055.html

EXPLORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34)

NIH: National Center for Complementary and Integrative Health

The goal of this R34 funding opportunity is to support early phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM as high priority research topics. Proposals may request up to $450,000 over a maximum of three years.

Closing date: 10 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-182.html#_Section_III._Eligibility

HUMAN CELL BIOLOGY OF GENETIC VARIANTS IN ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This aims to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease, in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 10 Feb 17
Website:

UNDERSTANDING THE EFFECTS OF APOLIPOPROTEIN E 2 ON THE INTERACTION BETWEEN AGEING AND ALZHEIMER'S DISEASE (R01)

NIH: National Institute on Aging

This seeks applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. Application budgets are worth up to USD 300,000 in direct costs per year for maximum period of five years.

Closing date: 10 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-056.html

LEVERAGING EXISTING RESOURCES FOR RESEARCH ON LEWY BODY DEMENTIA (R03)

NIH: National Institute of Neurological Disorders and Stroke

This supports applications proposing to investigate the clinical, imaging, or physiological characteristics of subjects with dementia and parkinsonism using previously-collected data available in the Alzheimer's Disease Neuroimaging Initiative/National Alzheimer's Coordinating Center or the Parkinson's Disease Biomarker Program databases. The total budget is worth USD 1 million in fiscal year 2017. Application budgets are worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 10 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-016.html

FRONTOTEMPORAL DEGENERATION SEQUENCING CONSORTIUM: DISCOVERY, REPLICATION AND VALIDATION (UG3/UH3)

NIH: National Institute of Neurological Disorders and Stroke

This supports the genetic discovery, replication and validation of disease causing mutations, risk variants and genetic modifiers which contribute to the pathophysiology, proteinopathies and clinical heterogeneity representative of the neurological syndromes that are classified under the broad spectrum of frontotemporal degeneration. Application budgets are worth up to USD 600,000 for the two-year UG3 phase; USD 750,000 for the three-year UH3 phase. The combined maximum project period is five years.

Closing date: 10 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-017.html

SINGLE-SITE INVESTIGATOR-INITIATED CLINICAL TRIALS (R61/R33)

NIH: National Heart, Lung and Blood Institute

This supports development and implementation of phase II and beyond investigator-initiated single-site clinical trials relevant to the research mission of the National Heart, Lung and Blood Institute. Application budgets are not limited but the maximum project period is five years.

Closing date: 14 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-405.html

NOVEL ANALYTICAL APPROACHES FOR METABOLOMICS DATA (R03)

NIH: Office of the Director

This aims to foster collaboration between computational scientists, metabolomics experts and biomedical researchers in developing, piloting and validating novel bioinformatic approaches that address current analytical hurdles in metabolomics data. The total budget is worth USD 1 million, to fund six to seven awards in fiscal year 2017. Application budgets are worth up to USD 100,000 for a maximum period of one year.

Closing date: 14 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-17-001.html

UTILISING THE PLCO BIOSPECIMENS RESOURCE TO BRIDGE GAPS IN CANCER AETIOLOGY AND EARLY-DETECTION RESEARCH (U01)

NIH: National Cancer Institute

This announcement seeks to advance research in cancer aetiology and early-detection biomarkers, using the advantages of the unique biorepository resources of the NCI-sponsored prostate, lung, colorectal and ovarian cancer screening trial. Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years.

Closing date: 15 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-297.html#_Section_II._Award_1

DEVELOPMENT OF PSYCHOSOCIAL THERAPEUTIC AND PREVENTIVE INTERVENTIONS FOR MENTAL DISORDERS (R61/R33)

NIH: National Institute of Mental Health

This supports efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum combined project period is five years

Closing date: 15 Feb 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-604.html

DEVELOPMENT OF PSYCHOSOCIAL THERAPEUTIC AND PREVENTIVE INTERVENTIONS FOR MENTAL DISORDERS (R33)

NIH: National Institute of Mental Health

This supports efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is three years.

Closing date: 15 Feb 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-606.html

CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R01)

NIH: National Institute of Mental Health

This supports clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators and mechanisms of action of these interventions. Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years but a three to four period is highly preferred

Closing date: 15 Feb 17

Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-608.html

CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (COLLABORATIVE R01)

NIH: National Institute of Mental Health

This supports clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators and mechanisms of action of these interventions. Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years but a three to four period is highly preferred.

Closing date: 15 Feb 17

Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-610.html

PILOT EFFECTIVENESS TRIALS FOR TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R34)

NIH: National Institute of Mental Health

This supports effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings and research on the development and preliminary testing of innovative services interventions. Application budgets are worth up to USD 450,000 over a three-year period. No more than USD 225,000 may be requested in any single year.

Closing date: 15 Feb 17

Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-612.html

CONFIRMATORY EFFICACY CLINICAL TRIALS OF NON-PHARMACOLOGICAL INTERVENTIONS FOR MENTAL DISORDERS (R01)

NIH: National Institute of Mental Health

This supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Applications budgets are not limited but need to reflect the actual needs of the proposed project. The maximum combined project period is five years, however, applicants are strongly encouraged to limit the period to three to four years.

Closing date: 15 Feb 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-614.html

CANCER-RELATED BEHAVIOURAL RESEARCH THROUGH INTEGRATING EXISTING DATA (R21)

NIH: National Cancer Institute

This announcement supports research that integrates two or more independent data sets to answer novel cancer control and prevention questions. Application budgets are limited to US$275,000 for period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 15 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-255.html

SUMMER CURRICULUM IN CANCER

NIH: National Cancer Institute

This enables individuals who have an interest in cancer prevention and control to take part in two courses. Financial support is available for select applications.

Closing date: 15 Feb 17
Website:
https://cpfp.cancer.gov/summer/summer.php

EARLY STAGE TESTING OF PHARMACOLOGIC OR DEVICE-BASED INTERVENTIONS FOR THE TREATMENT OF MENTAL DISORDERS (R33)

NIH: National Institute of Mental Health

This supports early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is three years.
Closing date: 15 Feb 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-602.html

NEI RESEARCH GRANT FOR VISION RELATED SECONDARY DATA ANALYSIS (R21)

NIH: National Eye Institute

This announcement encourages applications that propose to conduct vision-related secondary data analyses utilising existing database resources. Application budgets are limited to US$275,000 for a maximum period of two years. No more than US$200,000 may be requested in any single year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-168.html

IMAGING – SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)

NIH: National Institute on Drug Abuse

This announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to conduct small proof of concept studies. The award covers direct costs of up to US$150,000 for a maximum project period of one year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-326.html

EXPLORATORY OR DEVELOPMENTAL RESEARCH GRANT PROGRAMME (PARENT R21)

NIH: National Institutes of Health

This announcement encourages exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Application budgets are limited to US$275,000 for a two-year period, with no more than US$200,000 in any year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-161.html

PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-162.html

SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This Aids-related announcement supports the secondary analysis of existing data sets relevant to the following: diabetes and endocrine and metabolic diseases; genetic metabolic diseases; obesity, liver diseases, alimentary gastrointestinal tract diseases and nutrition; kidney, urologic and haematologic diseases. Application budgets are limited to a total of US$275,000 in direct costs over a maximum period of two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-169.html

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21)

NIH: National Institute of Nursing Research

This call aims to enhance our understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males across the life cycle, and encourage applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males age 18 and older. Application budgets are worth up to USD 275,000 for a maximum period of two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-432.html

ETHICAL, LEGAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH SMALL RESEARCH GRANT PROGRAMME (R03)

NIH: National Human Genome Research Institute

The purpose of this is to study the ethical, legal and social implications of human genome research. Application budgets are limited to no more than US$50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-277.html

EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement supports exploratory and developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and children. Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-163.html

SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT (R03)

NIH: National Institute of Dental and Craniofacial Research

This announcement supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or aims to develop needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial databases. Projects may receive up to US$100,000 per year for a maximum period of two years.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-15-344.html

DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R21)

NIH: National Institute of Mental Health

This announcement encourages investigators to submit research grant applications that will identify, develop, test, evaluate or refine strategies to disseminate and implement evidence-based practices, such as behavioural interventions, prevention, early detection, diagnostic, treatment and disease management interventions, quality improvement programs, into public health, clinical practice, and community settings. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-16-236.html

SMALL RESEARCH GRANT PROGRAMME (PARENT R03)

NIH: National Institute of Nursing Research

This announcement supports small research projects that can be carried out in a short period of time with limited resources. Application budgets are limited to US$50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-162.html

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment and recovery support services. Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-253.html

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement supports rigourous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. Application budgets are limited to US$50,000 in direct costs per year. The maximum project period is two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-252.html

DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R21)

NIH: National Institute on Drug Abuse

This announcement aims to support research that will employ rigourous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-080.html

DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03)

NIH: National Institute on Drug Abuse

This announcement aims to support research that will employ rigourous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. Direct costs of up to US$50,000 per year and a project duration of up to two years may be requested.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-081.html

BIOLOGY OF MANUAL THERAPIES (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-167.html

RESEARCH ON AUTISM SPECTRUM DISORDERS (R03)

NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to ASD. Direct costs are limited to USD 100,000 over a two-year project period, with not more than USD 50,000 in any year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-387.html

RESEARCH ON AUTISM SPECTRUM DISORDERS (R21)

NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to ASD. Application budgets are worth up to USD 275,000 for maximum period of two years. No more than USD 200,000 may be requested in any single year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-386.html

PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or selected endocrine and genetic metabolic diseases. Application budgets are limited to a total of US$275,000 in direct costs, with a maximum of US$200,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-176.html

EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21)

NIH: National Institute of Biomedical Imaging and Bioengineering

The purpose of this R21 funding opportunity announcement is to establish the feasibility of technologies, techniques or methods that: explore a unique multidisciplinary approach to a biomedical challenge, are high-risk but have high impact, and develop data that may lead to significant future research. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-040.html

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03)

NIH: National Institute on Drug Abuse

This aims to encourage investigators to propose well-defined projects within the domain of behavioural or integrated interventions that can be completed within two years. Application budgets are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-074.html

MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21)

NIH: National Cancer Institute

This announcement aims to inform the scientific community of the pain research interests of the various institutes and centres at the NIH, and aims to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these institutes and centres. Applications budgets are limited to US$275,000 in direct costs for a maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-187.html

DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21)

NIH: National Institute of Mental Health

This announcement aims to stimulate the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. Application budgets are limited to US$275,000 over two years, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-042.html

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21)

NIH: National Institute on Drug Abuse

This announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Application budgets are limited to US$275,000 with a maximum of US$200,000 in indirect costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-143.html

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03)

NIH: National Institute on Drug Abuse

This announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Application budgets are limited US$50,000 per year over a maximum project period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-141.html

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21)

NIH: National Institute on Drug Abuse

This call encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviours or treatment non-compliance. Direct costs are limited to US$275,000 over a two-year period.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-062.html

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03)

NIH: National Institute on Drug Abuse

This aims to stimulate research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-063.html

DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21)

NIH: Office of the Director

This announcement solicits proposals to develop, characterise or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes. Application budgets are limited to US$275,000 in direct costs over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-141.html

REDUCING HEALTH DISPARITIES AMONG MINORITY AND UNDERSERVED CHILDREN (R21)

NIH: National Cancer Institute

This encourages research that targets the reduction of health disparities among children. Application budgets are limited to USD 275,000 over a two-year period.

Closing date: 16 Feb 17
Website:
https://grants.nih.gov/grants/guide/pa-files/PA-17-117.html

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations. Application budgets are limited to US$275,000 and the maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-294.html

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations. Application budgets are up to US$50,000 per year in direct costs under a maximum project duration of up to two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-296.html

GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Direct costs are limited to US$50,000 per year with a maximum project period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-111.html

GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-112.html

SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03)

NIH: National Institute of Dental and Craniofacial Research

This supports pilot and developmental research with the intention of facilitating subsequent submission of an Individual research project grant (R01) application. Budgets for direct costs of up to US$150,000 over a two-year period may be requested.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-409.html

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

The goal of this R21 funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. Direct costs are limited to US$275,000 over a a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-188.html

EPIDEMIOLOGY OF DRUG ABUSE (R21)

NIH: National Institute on Drug Abuse

These support research projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Direct costs are limited to US$275,000.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-001.html

EPIDEMIOLOGY OF DRUG ABUSE (R03)

NIH: National Institute on Drug Abuse

This R03 funding opportunity announcement supports projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Funding is worth up to US$50,000 per year for a maximum project period of two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-002.html

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

These support investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. Grants are worth up to US$50,000 per year for direct costs over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-337.html

BEHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34)

NIH: National Institute of Dental and Craniofacial Research

These support activities that include, but are not limited to: the development of the behavioural or social intervention manual and procedures for training interventionists; development of the clinical protocol that will guide a subsequent clinical trial; the tools for data management, participant safety and operational oversight; and other activities to prepare for a subsequent clinical trial. Funding is worth up to US$150,000 for a period of maximum of one year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-342.html

RESEARCH TO ADVANCE VACCINE SAFETY (R21)

NIH: National Institute of Allergy and Infectious Diseases

This announcement supports research that will contribute to the overall understanding of vaccine safety. Direct costs are limited to US$275,000 over a two-year period.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-313.html

PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG AND ALCOHOL ABUSE PREVENTION TRIALS (R34)

NIH: National Institute on Drug Abuse

This announcement supports pilot and feasibility testing of innovative new, revised or adapted prevention intervention approaches, and pre-trial feasibility testing for prevention services and systems research. Application budgets are limited to a total of US$450,000 in direct costs with up to US$225,000 in direct costs per year. The maximum project period is three years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-177.html

DIET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement supports innovative research to enhance the quality of measurements of dietary intake and physical activity. Application budgets are limited to a total of US$275,000 in direct costs, with up to US$200,000 available for direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-171.html

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34)

NIH: National Institute on Drug Abuse

This aims to encourage investigators to propose discrete well-defined projects within the domain of behavioural or integrated interventions that can be completed within three years. Application budgets are limited to US$450,000 over three years, with no more than US$225,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-073.html

NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34)

NIH: National Eye Institute

This announcement is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed manual of procedures. Application budgets are limited to US$150,000 in direct costs per year. The maximum period is two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-038.html

SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03)

NIH: National Institute of Dental and Craniofacial Research

This supports meritorious research projects that involve statistical analysis of existing genome-wide data relevant to human dental, oral or craniofacial conditions or traits. Application budgets are limited to US$200,000 over a maximum project period of two years and no more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-070.html

DEADLINE BROUGHT FORWARD: SELECTED TOPICS IN TRANSFUSION MEDICINE (R21)

NIH: National Heart, Lung and Blood Institute

*** The National Heart, Lung and Blood Institute has brought forward the opening date and added an additional application due date for its selected topics in transfusion medicine (R21) funding opportunity announcement. The previous opening date of 5 January 2017 has been brought forward to 21 October 2016 and the additional application due date is 21 November 2016. All other call information remain unchanged. This call encourages applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Application budgets are worth up to USD 275,000 for maximum period of two years. No more than USD 200,000 may be requested in any single year. ***

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-441.html

MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are limited to US$100,000 over the maximum period of two years. No more than US$50,000 in direct costs may be requested in any single year.
Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-101.html

MULTIDISCIPLINARY RESEARCH IN VULVODYNIA (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are limited to US$275,000 over the maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-100.html

RESEARCH ON HEARING HEALTHCARE (R21)

NIH: National Institute on Deafness and other Communication Disorders

This R21 funding opportunity announcement supports research leading to accessible and affordable hearing healthcare. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-090.html

NEUROBIOLOGY OF MIGRAINE (R21)

NIH: National Institute of Neurological Disorders and Stroke

These R01 grants support research elucidating the mechanisms underlying migraine, expanding our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression, and exploring new therapeutic targets and therapies for acute

migraine management and longer term prevention.
Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-069.html

CHEMICAL DISCOVERY AWARD (R21/R33)

NIH: National Institute on Drug Abuse

This supports the development of chemical probes that aid basic research investigations on substance use disorders or identify new lead chemical scaffolds with potential for structure activity relationship studies on SUDs. Direct costs are limited to USD 275,000 over a R21 two-year period, with a maximum of US$200,000 allowed in any single year. The R33 award phase will be limited to USD 250,000 in direct costs per year for a maximum period of three years. The total project period may not exceed four years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-384.html

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

These R03 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation. Application budgets are limited to US$50,000 in direct costs per year over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-351.html

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

These R21 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation. Application budgets are limited to US$275,000 over a maximum of two years, and no more than US$200,000 may be requested in a single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

The purpose of this R21 funding opportunity announcement is to encourage a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Application budgets are limited to direct costs of up US$275,000 over a two-year project period and no more than US$200,000 may be requested in any one year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-311.html

SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21)

NIH: National Cancer Institute

This R21 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty. Funding is worth up to US$275,000 over a maximum two-year project period.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-009.html

SPATIAL UNCERTAINTY: DATA, MODELLING AND COMMUNICATION (R03)

NIH: National Cancer Institute

This R03 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty. Funding is worth up to US$50,000 per year over a maximum two-year project period.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-011.html

LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH EXPLORATORY/DEVELOPMENTAL RESEARCH PROGRAMME (R21)

NIH: National Human Genome Research Institute

The purpose of this R21 funding opportunity is to study the ethical, legal and social implications of human genome research. Application budgets are limited to no more than US$275,000 in direct costs for up to two years, with no more than US$200,000 in direct costs in a single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-278.html

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21)

NIH: National Institute of Mental Health

This funding opportunity announcement uses the R21 mechanism to encourage new research activities directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. Direct costs are limited to US$275,000 over a two year period, with no more than US$200,000 in direct costs in any one year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-310.html

SYSTEMS SCIENCE AND HEALTH IN BEHAVIOURAL AND SOCIAL SCIENCES (R21)

NIH: Office of the Director

This R21 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. Application budgets are limited to US$275,000 over the two-year R21 period, with no more than US$200,000 in any year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-047.html

HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21)

NIH: National Institute of Nursing Research

This R21 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-176.html

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21)

NIH: National Institute of Nursing Research

The purpose of this R21 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. he combined budget for direct costs for the two year project period may not exceed US$275,000 and no more than US$200,000 may be requested in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-14-181

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-181.html

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. Application budgets are limited to US$100,000 over a two-year project period.

Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-262.html

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. Application budgets are limited to US$275,000 over a two-year project period.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-263.html

PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34)

NIH: National Institute on Drug Abuse

This announcement encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials into the quality, effectiveness, affordability and utilisation of drug, tobacco or alcohol use disorder treatments. Application budgets are limited to a total of US$450,000 in direct costs with up to US$225,000 in direct costs per year. The maximum project period is three years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-250.html

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R21)

NIH: National Institute of Nursing Research

This R21 funding opportunity announcement encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health

disparities in non-traditional settings where exposure to environmental pollutants and toxins may occur. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-273.html

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS – EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21)

NIH: National Cancer Institute

This announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-123.html

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R21 announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries. Grants cover direct costs up to a maximum of US$275,000 over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-057.html

EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21)

NIH: National Cancer Institute

This announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Application budgets are limited to US$275,000 per year for a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-011.html

DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03)

NIH: National Institute of Mental Health

This supports research that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures and strategies to disseminate and implement evidence-based health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services into public health, clinical practice and community settings. Application budgets are limited to $50,000 in direct costs per year for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-237.html

IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R21)

NIH: Office of the Director

This announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. Application budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-094.html

SMALL RESEARCH GRANTS FOR SECONDARY ANALYSIS OF FACEBASE DATA (R03)

NIH: National Institute of Dental and Craniofacial Research

These support research projects that conduct secondary data analyses of the FaceBase Consortium datasets relevant to craniofacial development, human craniofacial conditions or traits and animal models of those conditions. Application budgets are worth up to US$200,000 over two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-362.html

EXTENDED DEADLINE: ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21)

NIH: National Institute on Aging

*** The National Institute on Aging, the National Institute of Nursing Research and the National Cancer Institute have extended the expiration date for their advancing the science of geriatric palliative care (R21) funding opportunity announcement. The previous expiration date of 8 January has now been extended to 8 May 2017. All other call information remain the same. This announcement encourages research grant applications focused on palliative care in geriatric populations. The total project period may not exceed two years; the combined budget for direct costs over this period may not exceed USD 275,000.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/notice-files/NOT-AG-16-075.html

NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21)

NIH: National Institute on Drug Abuse

This R21 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03)

NIH: National Institute on Drug Abuse

This R03 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies. The combined budget for direct costs for the maximum two year project period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-104.html

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21)

NIH: National Institute on Drug Abuse

This R21 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies. The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-105.html

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21)

NIH: National Institute of Nursing Research

This R21 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions. The combined budget for direct costs may not exceed US$275,000 over a two-year project period, and no more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-113.html

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R21 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-124.html

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34)

NIH: National Institute on Drug Abuse

This R34 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. The combined budget for direct costs for the maximum three year project period may not exceed US$450,000. No more than US$225,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-135.html

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21)

NIH: National Institute on Drug Abuse

This R21 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-136.html

NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This R21 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-138.html

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21)

NIH: National Institute of Nursing Research

This R21 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-141.html

ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21)

NIH: National Institute of Dental and Craniofacial Research

This R21 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-144.html

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21)

NIH: National Institute on Aging

This R21 funding opportunity announcement supports translational research collaborations to develop tools, techniques, programmes or policies to respond to the needs of the ageing population. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-159.html

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21)

NIH: National Institute on Drug Abuse

This R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03)

NIH: National Institute on Drug Abuse

This R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans. Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-164.html

ADVANCING RESEARCH IN VOICE DISORDERS (R21)

NIH: National Institute on Deafness and other Communication Disorders

The purpose of this R21 funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. The combined budget for direct costs for the two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. The total project period may not exceed two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-235.html

RESEARCH ON CHRONIC OVERLAPPING PAIN CONDITIONS (R21)

NIH: National Institute of Neurological Disorders and Stroke

This supports epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. The combined budget for direct costs for the two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. The project period is limited to two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-243.html

HIGH THROUGHPUT SCREENING (HTS) TO DISCOVER CHEMICAL PROBES (R21)

NIH: National Institutes of Health

This aims to encourage investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Funding covers the total direct costs of US$275,000 over an R21 two-year period for each award, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-283.html

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This R03 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. Funding is worth up to US$50,000 per year for a maximum project period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-313.html

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

These R21 grants support investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. Grants are worth up to US$275,000 in direct costs over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-336.html

SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21)

NIH: National Institute of Nursing Research

These R21 grants support research in self-management focused across conditions. The combined budget for direct costs for the two-year project period may not exceed US$275,000. The maximum project period is two years.

Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-343.html

NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34)

NIH: National Institute of Dental and Craniofacial Research

This R34 call for funding supports activities to develop a draft clinical protocol, the clinical investigators brochure, tools for data and quality management, safety and operational oversight plans, recruitment and retention strategies, a study team and other essential documents. Direct costs may not exceed US$150,000 over a period of one year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-346.html

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21)

NIH: National Institute of Dental and Craniofacial Research

This R21 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Funding is worth up to US$275,000 over two years, and projects may request no more than US$200,000 per year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-359.html

BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21)

NIH: National Institutes of Health

These R21 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Grants cover direct

costs up to a maximum of US$275,000 over a period of up to two years.

Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-015.html

RESEARCH ON EOSINOPHIL ASSOCIATED DISORDERS (R21)

NIH: National Institute of Allergy and Infectious Diseases

These R21 grants encourage research aimed at elucidating the pathophysiology of eosinophil-associated disorders and clarifying the cellular and molecular mechanisms underlying the role of eosinophil leukocytes in these conditions. Application budgets are limited to US$275,000 for direct costs. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-028.html

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03)

NIH: National Institute on Aging

These R03 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Application budgets are limited to US$100,000 for direct costs over a maximum project period of two years. No more than US$50,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-039.html

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21)

NIH: National Institute on Aging

These R21 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and

cardiovascular disease complications in older persons or animal models. Application budgets are limited to US$275,000 for direct costs over a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-038.html

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33)

NIH: National Institute of Neurological Disorders and Stroke

This announcement provides funding to conduct pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological disorders. Application budgets are limited to US$750,000 over the entire three-year period, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-071.html

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33)

NIH: National Institute of Neurological Disorders and Stroke

This announcement encourages research to develop in vitro or ex vivo assays and conduct iterative screening efforts to identify and characterise potential therapeutic agents for neurological disorders. Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-071.html

PREVENTION RESEARCH IN MID-LIFE ADULTS (R21)

NIH: National Institute of Nursing Research

This announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. The combined application budget is limited to US$275,000 in direct costs over a two-year period. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-097.html

REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33)

NIH: National Institute on Drug Abuse

This announcement encourages research that determines whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders. The R21 phase may request up to two years of support for a maximum of US$275,000 in direct costs. The R33 phase may request up to three years of support for a maximum of US$500,000 in direct costs per year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-099.html

NOVEL BIOMARKERS FOR THE DEVELOPMENT OF HIV INCIDENCE ASSAYS WITH IMPROVED SPECIFICITY (R21)

NIH: National Institute of Allergy and Infectious Diseases

This announcement supports projects that seek to develop novel biomarkers and improved HIV incidence assays and algorithms, with increased specificity for distinguishing incident from chronic HIV infections. Application budgets are limited to US$275,000 in direct costs over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-106.html

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03)

NIH: National Cancer Institute

This announcement stimulates research focused on the role of early-life factors in cancer development in later life. Projects may include pilot or feasibility studies, secondary analysis of existing data, small and self-contained research projects, the development of research methodology or the development of new research technology. Awards are worth up to US$100,000 each in direct costs over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-124.html

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21)

NIH: National Cancer Institute

This announcement stimulates research focused on the role of early-life factors in cancer development in later life. Awards are worth up to US$275,000 each in direct costs over a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-125.html

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R21)

NIH: National Institute of Nursing Research

This announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. The combined budget for direct costs over the two-year project period may not exceed US$275,000, with no more than US$200,000 requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-134.html

PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney diseases research. Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-15-161.html

IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21)

NIH: National Institute of Dental and Craniofacial Research

This announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year. The maximum project period is two years.
Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-15-193.html

STUDIES AT PERIVIABLE GESTATION (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. Application budgets are limited to a total of US$100,000 in direct costs with up to US$50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PA-15-199.html

STUDIES AT PERIVIABLE GESTATION (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-198.html

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder. Application budgets are limited to a total of US$100,000 in direct costs with up to US$50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-255.html

HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder. Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-254.html

PILOT SERVICES RESEARCH GRANTS NOT INVOLVING INTERVENTIONS (R34)

NIH: National Institute of Mental Health

This call aims to encourage pilot research consistent with NIMH priorities for services research studies that are not immediate precursors to the development and testing of services interventions. Direct costs are limited to US$450,000 over the project period, with no more than US$225,000 in direct costs allowed in any one year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-323.html

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R21)

NIH: National Institute of Nursing Research

This announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Application budgets may not exceed US$275,000 over the maximum project period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-15-325.html

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R21)

NIH: National Institute of Nursing Research

This announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. Application budgets are limited to US$275,000 for the maximum project period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-008.html

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R21)

NIH: National Institute of Nursing Research

This announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science. Application budgets are limited to US$275,000 and no more than US$200,000 may be requested in any single year. The maximum project period is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-023.html

APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R21)

NIH: National Institute of Nursing Research

This announcement encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. The combined budget for direct costs excluding consortia facilities and administration costs for the maximum two year project period is US$275,000. No more than US$200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-029.html

ADVANCING UNDERSTANDING, PREVENTION AND MANAGEMENT OF INFECTIONS TRANSMITTED FROM WOMEN TO THEIR INFANTS (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will increase scientific understanding of and treatments for high-priority perinatal infections. Application budgets are limited to US$275,000 in direct costs for the maximum project period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-031.html

IMPROVING OUTCOMES IN CANCER TREATMENT-RELATED CARDIOTOXICITY (R21)

NIH: National Cancer Institute

This announcement supports collaborative projects that will contribute to the identification and characterisation of patients at risk of developing cancer treatment-related cardiotoxicity. The total budget is worth up to US$275,000 over a maximum period of two years.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-036.html

OOCYTE MITOCHONDRIAL FUNCTION IN RELATION TO FERTILITY, AGEING AND MITOCHONDRIAL DISEASES (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring. Application budgets are limited to US$275,000 for the maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-087.html

ACCELERATING RESEARCH ON INTERVERTEBRAL DISC (R21)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This announcement encourages studies on basic biology of the intervertebral disc and seeks applications that accelerate an understanding of basic research on the intervertebral disc and develop new directions on the factors that lead to disc degeneration. Application budgets are limited to US$275,000 for the maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-096.html

USING THE NIMH RESEARCH DOMAIN CRITERIA APPROACH TO UNDERSTAND PSYCHOSIS (R21)

NIH: National Institute of Mental Health

This announcement seeks seeks applications which propose research studies that will use the NIMH's research domain criteria framework to advance scientific understanding of neurobehavioral mechanisms related to psychotic symptoms such as hallucinations, delusions, disorganised behaviour, and thought disorder. Application budgets are limited to US$275,000 and no more than US$200,000 may be requested in any single year. The maximum period of performance is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-135.html

ROLE OF ASTROCYTES AND ASTROCYTIC NETWORKS IN DRUG ABUSE (R21)

NIH: National Institute on Drug Abuse

This announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Application budgets are limited to US$275,000 in direct costs over a maximum period of two years. No more than US$200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-145.html

POPULATION HEALTH INTERVENTIONS: INTEGRATING INDIVIDUAL AND GROUP LEVEL EVIDENCE (R21)

NIH: Office of the Director

This announcement supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application budgets are limited to US$275,000 in direct costs over the maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-147.html

TAILORING DENTAL TREATMENT FOR INDIVIDUALS WITH SYSTEMIC DISEASES THAT COMPROMISE ORAL HEALTH (R21)

NIH: National Institute of Dental and Craniofacial Research

This announcement aims to encourage developmental or exploratory clinical research related to addressing gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. Application budgets are limited to US$275,000 in direct costs over the maximum two year period. No more than US$200,000 is allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-153.html

EXTENDED DEADLINE: PILOT AND FEASIBILITY STUDIES EVALUATING THE ROLE OF RIBONUCLEIC ACID MODIFICATIONS IN CANCER BIOLOGY (R21)

NIH: National Cancer Institute

*** The National Cancer Institute has extended the expiration date for its pilot and feasibility studies evaluating the role of ribonucleic acid modifications in cancer biology (R21) funding opportunity announcement. The previous expiration date of 17 June 2019 has been extended to 17 July 2019. All other call information remain unchanged. This announcement encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. Applications budgets are limited to US$275,000 in direct costs over the maximum period of two years. No more than US$200,000 may be requested in any single year. ***

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/notice-files/NOT-CA-16-050.html

ROLE OF MOBILE GENETIC ELEMENTS IN CANCER (R21)

NIH: National Institutes of Health

This R21 funding opportunity announcement encourages applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer. Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.
Closing date: 16 Feb 17

Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-226.html

METABOLIC REPROGRAMMING TO IMPROVE IMMUNOTHERAPY (R21)

NIH: National Cancer Institute

This announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the tumour, the immune response, or both to improve cancer immunotherapy. Application budgets are limited to US$275,000 over a maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-229.html

NON-HEALING ULCERATIVE WOUNDS IN AGEING (R21)

NIH: National Institute on Aging

This announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are limited to US$275,000 for a maximum period of two years. No more than US$200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-231.html

MECHANISMS MEDIATING OSTEOARTHRITIS IN AGEING (R21)

NIH: National Institute on Aging

This funding opportunity announcement encourages exploratory/development applications to accelerate the characterisation of new paradigms to test hypotheses that will

lead to an improved understanding of the mechanisms of initiation and progression of osteoarthiritis and the role of the ageing process. Application budgets are limited to US$275,000 direct cost funding for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-240.html

NOVEL APPROACHES TO UNDERSTANDING, PREVENTING AND TREATING LYME DISEASE AND TICK-BORNE COINFECTIONS (R21)

NIH: National Institute of Allergy and Infectious Diseases

This R21 funding opportunity announcement supports research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by Ixodes ticks. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-244.html

GENE FUSION IN PAEDIATRIC SARCOMAS (R21)

NIH: National Cancer Institute

This R21 funding opportunity announcement encourages applications that explore the molecular biology of paediatric sarcomas to elucidate molecular mechanisms by which fusion genes and the resulting protein products drive tumorigenesis and cancer progression. Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-252.html

MECHANISMS OF CANCER AND TREATMENT-RELATED SYMPTOMS AND TOXICITIES (R21)

NIH: National Cancer Institute

This supports innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioural and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout the cancer care trajectory.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-258.html

STIMULATING INNOVATIONS IN BEHAVIOURAL INTERVENTION RESEARCH FOR CANCER PREVENTION AND CONTROL (R21)

NIH: National Cancer Institute

This supports the development of innovative interventions that improve cancer-related health behaviours across diverse racial or ethnic populations. Application budgets are limited to US$275,000 over a two-year period with no more than US$200,000 in direct costs allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-278.html

INTEGRATIVE RESEARCH ON POLYSUBSTANCE ABUSE AND ADDICTION (R21/R33)

NIH: National Institute on Drug Abuse

This seeks applications to characterise how the neurobiological alterations, associated behaviours, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use and to promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations and epidemiological studies. Application budgets are worth up to US$1.77 million for a maximum period of five years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-291.html

INTEGRATIVE RESEARCH ON POLYSUBSTANCE ABUSE AND ADDICTION (R21/R33): AIDS-RELATED

NIH: National Institute on Drug Abuse

This Aids-related announcement seeks applications to characterise how the neurobiological alterations, associated behaviours, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use and to promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations and epidemiological studies. Application budgets are worth up to US$1.77 million for a maximum period of five years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-291.html

FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R21)

NIH: National Institute of Dental and Craniofacial Research

This supports exploratory or development research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are worth up to US$275,000 in direct costs for a two-year project period, with no more than US$200,000 allowed for any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-296.html

FACTORS UNDERLYING DIFFERENCES IN FEMALE AND MALE PRESENTATION FOR DENTAL, ORAL AND CRANIOFACIAL DISEASES AND CONDITIONS (R21): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

This Aids-related announcement supports exploratory or development research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are worth up to US$275,000 in direct costs for a two-year project period, with no more than US$200,000 allowed for any single year.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-296.html

CHARACTERISATION OF THE ADOLESCENT REPRODUCTIVE TRANSITION (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports outstanding research in the area of puberty and the trajectory of sexual development. Application budgets are worth up to US$50,000 in direct costs per year for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-316.html

CHARACTERISATION OF THE ADOLESCENT REPRODUCTIVE TRANSITION (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports outstanding research in the area of puberty and the trajectory of sexual development. Application budgets are worth up to US$275,000 for a maximum period of two years, with no more than US$200,000 allowed in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-315.html

SAFETY AND OUTCOME MEASURES OF PAIN MEDICATIONS USED IN CHILDREN AND PREGNANT WOMEN (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations and develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments. Application budgets are worth up to US$50,000 per year for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-313.html

SAFETY AND OUTCOME MEASURES OF PAIN MEDICATIONS USED IN CHILDREN AND PREGNANT WOMEN (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations and develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments. Application budgets are worth up to US$275,000 in direct costs for a maximum period of two years and no more than US$200,000 may be requested for any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-312.html

SMALL RESEARCH GRANTS FOR ANALYSES OF DATA FOR THE GABRIELLA MILLER KIDS FIRST DATA RESOURCE (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports meritorious small research projects focused on the development and analyses of childhood cancer and structural birth defects datasets that are part of the kids first data resource or could be included in the kids first data resource. Application budgets are worth up to US$200,000 for a maximum period of two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-348.html

TARGET ASSESSMENT, ENGAGEMENT AND DATA REPLICABILITY TO IMPROVE SUBSTANCE USE DISORDERS TREATMENT OUTCOMES (R33)

NIH: National Institute on Drug Abuse

This supports applications that focus on data replication and the scalability of novel, targeted addiction treatments. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is three years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-352.html

TARGET ASSESSMENT, ENGAGEMENT AND DATA REPLICABILITY TO IMPROVE SUBSTANCE USE DISORDERS TREATMENT OUTCOMES (R21/R33)

NIH: National Institute on Drug Abuse

This supports applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. Application budgets for the R21 phase are worth up to US$275,000 in direct costs for a maximum project period of two years, with no more than US$200,000 allowed in any single year. The R33 phase budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period for the R33 phase is three years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-353.html

PHENOTYPIC AND FUNCTIONAL CHARACTERISATION OF APOLIPOPROTEIN E TWO TO INFORM TRANSLATION STRATEGIES FOR AGEING-RELATED CONDITIONS (R21)

NIH: National Institute on Aging

This supports exploratory and developmental new research activities on ApoE2 and other variants to improve understanding of physiologic and cellular differences attributable to the ApoE e2 allele, versus other ApoE alleles, and how they mediate ApoE e2's differential effects on longevity and risk for age-related conditions. Application budgets are worth up to US$275,000 for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-371.html

ENGINEERING NEXT-GENERATION HUMAN NERVOUS SYSTEM MICROPHYSIOLOGICAL SYSTEMS (R21)

NIH: National Institute of Mental Health

This announcement aims to stimulate basic research to develop next-generation human cell-derived microphysiological systems with improved fidelity to complex human brain, spinal, peripheral nervous system and sensory end organ circuit physiology in vivo. Funding is worth up to USD 200,000 per year for up to two years.
Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-397.html

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data. Application budgets are limited to USD 50,000 in direct costs per year. The maximum project duration is two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-394.html

SYMPTOM MANAGEMENT IN HIV-INFECTED INDIVIDUALS WITH COMORBID CONDITIONS (R21)

NIH: National Institute of Nursing Research

This call seeks research applications focused on developing, adapting and testing innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated Non-AIDS conditions and other comorbidities among older adults with prolonged HIV infection. Application budgets are worth up to USD 275,000 for maximum period of two years. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-429.html

BASIC AND TRANSLATIONAL RESEARCH ON DECISION MAKING IN AGEING AND ALZHEIMER'S DISEASE (R21)

NIH: National Institute on Aging

This seeks applications for basic research to better characterise the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal ageing and Alzheimer's disease. Application budgets are limited to USD 275,000 for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-449.html

TROPHOBLAST DIFFERENTIATION AND FUNCTION (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages applications from the scientific community to support outstanding research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. Application budgets are worth up to USD 275,000 for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-16-444.html

PALLIATIVE CARE NEEDS OF INDIVIDUALS WITH RARE ADVANCED DISEASES AND THEIR FAMILY CAREGIVERS (R21)

NIH: National Institute of Nursing Research

This aims to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers. Application budgets are worth up to USD 275,000 for a two-year project period. No more than USD 200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-017.html

IMPROVING INDIVIDUAL AND FAMILY OUTCOMES THROUGH CONTINUITY AND CO-ORDINATION OF CARE IN HOSPICE (R21)

NIH: National Institute of Nursing Research

This seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimising the individual and family outcomes related to high quality co-ordination of care of individuals who are enrolled in hospice. Application budgets are worth up to USD 275,000 for a two-year project period. No more than USD 200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-015.html

ADDRESSING UNMET NEEDS IN PERSONS WITH DEMENTIA TO DECREASE BEHAVIOURAL SYMPTOMS AND IMPROVE QUALITY OF LIFE (R21)

NIH: National Institute of Nursing Research

This aims to stimulate clinical research addressing behavioural and psychological symptoms of dementia and the association of BPSD with unmet physical, social or environmental needs in persons with dementia. Application budgets are worth up to USD 275,000 for a two-year project period. No more than USD 200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-013.html

SELF-MANAGEMENT INTERVENTIONS AND TECHNOLOGIES TO SUSTAIN HEALTH AND OPTIMISE FUNCTIONAL CAPABILITIES (R21)

NIH: National Institute of Nursing Research

This seeks clinical research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimise and maintain existing functional capabilities, prevent or delay disabilities and navigate their environment. Application budgets are worth up to USD 275,000 for a two-year project period. No more than USD 200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-011.html

USE OF TECHNOLOGY TO ENHANCE PATIENT OUTCOMES AND PREVENT ILLNESS (R21)

NIH: National Institute of Nursing Research

This seeks clinical research focused on the development and utilisation of technologies that can help address patient outcomes. Application budgets are worth up to USD 275,000 for a two-year period. No more than USD 200,000 in direct costs may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-009.html

IMPROVING QUALITY OF CARE AND QUALITY OF LIFE FOR PERSONS WITH ALZHEIMER'S DISEASE AND RELATED DEMENTIAS AT THE END OF LIFE (R03)

NIH: National Institute on Aging

This seeks applications that propose analysis of secondary data, to address clinical and translational gaps in the study of end-of-life care needs of people with Alzheimer's disease or related dementias and their families. Application budgets are worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAS-17-026.html

CLARIFYING THE RELATIONSHIP BETWEEN DELIRIUM AND ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (R21/R33)

NIH: National Institute on Aging

This aims to clarify the relationship between delirium and Alzheimer's disease and related dementias. Application budgets are worth up to USD 275,000 in direct costs over the two-year R21 phase, with no more than USD 200,000 allowed in any years. For the three-year R33 phase, budgets are worth less than USD 500,000 in annual direct costs.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-037.html

ORAL ANTICANCER AGENTS: UTILISATION, ADHERENCE AND HEALTH CARE DELIVERY (R21)

NIH: National Cancer Institute

This aims to assess and describe the current state of oral anticancer medication utilisation, delivery and adherence, identify structural, systemic, and psychosocial barriers to adherence and develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimised. Application budgets are worth up to USD 275,000 for a maximum two-year period. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-17-061.html

CLINICAL TRIAL READINESS FOR RARE NEUROLOGICAL AND NEUROMUSCULAR DISEASES (U01)

NIH: National Institute of Neurological Disorders and Stroke

This announcement supports clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers or by characterising cohorts of relevant patients. Application budgets are not limited but need to reflect the actual needs of the proposes project. The maximum project period is five years.

Closing date: 17 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-020.html

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS – DEVELOPMENT AND VALIDATION OF MODEL SYSTEMS AND PHARMACODYNAMIC MARKERS TO FACILITATE THE DISCOVERY OF NEUROTHERAPEUTICS (R21/R33)

NIH: National Institute of Neurological Disorders and Stroke

This announcement aims to develop and validate animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. Direct costs are limited to US$250,000 per year regardless of grant phase. The project period is limited to three years, with no more than two years in either phase.

Closing date: 21 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-16-013.html

DEADLINE BROUGHT FORWARD: CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21)

NIH: National Cancer Institute

*** The National Cancer Institute has changed the call schedule for its clinical and translational exploratory or developmental studies (R21) funding opportunity announcement. Please refer to the call schedule to view changes and exact dates. All other call information remains unchanged. This supports new exploratory research in cancer diagnosis, treatment, imaging, symptom or toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom or toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies. Application

budgets are limited to USD 275,000 in direct costs per year for the maximum period of two years. No more than USD 200,000 may be requested in any single year. ***

Closing date: 21 Feb 17
Website:
http://grants.nih.gov/grants/guide/notice-files/NOT-CA-16-065.html

INTERDISCIPLINARY RESEARCH TO UNDERSTAND THE COMPLEX BIOLOGY OF RESILIENCE TO ALZHEIMER'S DISEASE RISK (R01)

NIH: National Institute on Aging

This seeks comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. The total budget is worth USD 4.5 million to fund three to four awards in fiscal year 2017.

Closing date: 21 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-061.html

PLANNING GRANT FOR EMERGING EPIDEMIC VIRUS RESEARCH TRAINING FOR WEST AFRICAN COUNTRIES WITH WIDESPREAD TRANSMISSION OF EBOLA – GUINEA, LIBERIA AND SIERRA LEONE (D71)

NIH: Fogarty International Center

This announcement enables US or African research institutions to plan research training and capacity building programmes focused on emerging viral epidemics, in collaboration with institutions in Guinea, Liberia and Sierra Leone. Grants are worth up to USD 50,000 each for a maximum period of one year.

Closing date: 22 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-407.html

EXTENDED DEADLINE: GLOBAL NON-COMMUNICABLE DISEASES AND INJURY ACROSS THE LIFESPAN: EXPLORATORY RESEARCH (R21)

NIH: Fogarty International Center

*** The National Institute of Health and its eleven participating offices and institutes, have added an additional due date for their global non-communicable diseases and injury across

the lifespan: exploratory research (R21) funding opportunity announcement. In addition to the due dates of 24 February 2016 and 22 February 2017, applicants may now submit on 14 December 2017 as well. All other all information remain unchanged. This announcement supports planning, design, and initial pilots for locally relevant and catalytic research on non-communicable diseases or injury in low and middle-income countries. Application budgets are limited to USD 125,000 per year in direct costs for a maximum period of two years. ***

Closing date: 22 Feb 17
Website:
http://grants.nih.gov/grants/guide/notice-files/NOT-TW-17-001.html

NEURAL REGULATION OF CANCER (R21)

NIH: National Cancer Institute

This announcement encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year.

Closing date: 22 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-246.html

NEURAL REGULATION OF CANCER (R01)

NIH: National Cancer Institute

This announcement encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Closing date: 22 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-245.html

RESEARCH GRANTS FOR TRANSLATING BASIC RESEARCH INTO CLINICAL TOOLS (R01)

NIH: National Institute on Deafness and other Communication Disorders

The aim of this funding opportunity announcement is to provide a new avenue for basic scientists, clinicians and clinical scientists to conduct translational research projects. Applications budgets are not limited but must reflect the actual needs of the proposed project.

The maximum duration of a project is five years.

Closing date: 23 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-009.html

NOVEL ASSAYS TO ADDRESS TRANSLATIONAL GAPS IN TREATMENT DEVELOPMENT (UG3/UH3)

NIH: National Institute of Mental Health

This announcement aims to improve the efficiency of the therapeutic development process by addressing inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 23 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-065.html

1440 AWARDS FOR CONTEMPLATIVE EDUCATION RESEARCH

Mind & Life Institute

These support research that evaluates the effectiveness of mindfulness, compassion, or other contemplative interventions in K-12 classrooms, with a focus on evaluating inner well-being and healthy relationships for students and teachers. The award is worth up to USD 25,000, and is available for two years from the date of notification of acceptance.

Closing date: 24 Feb 17
Website:
http://www.mindandlife.org/grants/1440-awards/

SECONDARY ANALYSES OF EXISTING DATASETS IN HEART, LUNG AND BLOOD DISEASES AND SLEEP DISORDERS (R21)

NIH: National Heart, Lung and Blood Institute

This aims to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioural research in areas relevant to the NHLBI mission. Application budgets are worth up to USD 150,000 for a two year period. No more than USD 75,000 is allowed in any single year.

Closing date: 24 Feb 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-004.html

ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING BIOSPECIMEN SCIENCE TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33)

NIH: National Cancer Institute

This seeks exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. Application budgets are limited to USD 300,000 in direct costs per year for a maximum period of three years.

Closing date: 28 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-013.html

INNOVATIVE TECHNOLOGIES FOR CANCER-RELEVANT BIOSPECIMEN SCIENCE (R21)

NIH: National Cancer Institute

This seeks exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. Application budgets are limited to USD 400,000 over a three-year period, with no more than USD 200,000 in direct costs allowed in any single year.

Closing date: 28 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-012.html

ADVANCED DEVELOPMENT AND VALIDATION OF EMERGING MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R33)

NIH: National Cancer Institute

This seeks exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. The total budget is worth USD 4 million to fund up to 10 awards in fiscal year 2018. Applications budgets are limited to USD 300,000 per year for a maximum period of three years.

Closing date: 28 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-011.html

INNOVATIVE MOLECULAR AND CELLULAR ANALYSIS TECHNOLOGIES FOR BASIC AND CLINICAL CANCER RESEARCH (R21)

NIH: National Cancer Institute

This seeks exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. Application budgets are worth up to USD 400,000 per year over a three year period, with no more than USD 200,000 allowed in any single year.

Closing date: 28 Feb 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-010.html

MARCH 2017

IDENTIFICATION OF GENETIC AND GENOMIC VARIANTS BY NEXT-GEN SEQUENCING IN NON-HUMAN ANIMAL MODELS (U01)

NIH: National Institute on Drug Abuse

This announcement aims to to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of next gen-sequencing, mapping and genotyping. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 01 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html

BIOLOGICAL COMPARISONS IN PATIENT-DERIVED MODELS OF CANCER (U01)

NIH: National Cancer Institute

This seeks applications wherein similarities and differences in the underlying biological mechanisms, that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample, are delineated and compared. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 01 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-344.html

ACADEMIC-INDUSTRIAL PARTNERSHIPS TO TRANSLATE AND VALIDATE IN VIVO CANCER IMAGING SYSTEMS (R01)

NIH: National Cancer Institute

This aims to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and disease status. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.
Closing date: 01 Mar 17

Website:
https://grants.nih.gov/grants/guide/pa-files/PAR-17-093.html

ADMINISTRATIVE SUPPLEMENTS FOR RESEARCH ON SEXUAL AND GENDER MINORITY POPULATIONS

NIH: National Institutes of Health

This announcement provides administrative supplements for expanding existing research on sexual and gender minority populations health, including lesbian, gay, bisexual, transgender people, and individuals with differences or disorders of sexual development. NIH and partner ICOs intend to commit up to USD 1 million in fiscal year 2016 to fund approximately 10 awards. Application budgets must reflect the actual needs of the proposed project and must not exceed USD 100,000 in total costs. The maximum project period is one year.

Closing date: 01 Mar 17
Website:
https://grants.nih.gov/grants/guide/pa-files/PA-17-098.html

PARTNERSHIPS FOR DEVELOPMENT OF VACCINES TO PREVENT MYCOBACTERIUM TUBERCULOSIS INFECTION AND TUBERCULOSIS DISEASE (R01)

NIH: National Institute of Allergy and Infectious Diseases

This seeks applications for milestone-driven projects focused on establishing proof-of-concept for and preclinical development of lead candidate vaccines targeting infection with Mtb and TB. Application budgets are worth up to USD 750,000 per year plus an additional USD 300,000 in the first year for major equipment. The maximum project period is five years.

Closing date: 02 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-079.html

T CELL REAGENT RESEARCH FOR THE STUDY OF ALLERGIC DISEASES (U19)

NIH: National Institute of Allergy and Infectious Diseases

This call supports studies to understand the role of allergen epitope-specific T-cell responses in the pathogenesis and treatment of allergic diseases by utilising allergen epitope-specific reagents. Application budgets are worth up to USD 600,000 in direct costs per year for a maximum period of five years.

Closing date: 03 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-027.html

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This R01 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. The total project period may not exceed five years.

Closing date: 05 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html

INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01)

NIH: National Institute of Allergy and Infectious Diseases

This supports clinical trials of any phase that require an extended project period of six or seven years and are hypothesis-driven and related to the research mission of one of the participating institutes. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is seven years.

Closing date: 07 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-056.html

BRAIN INITIATIVE: EXPLORATORY TARGETED BRAIN CIRCUITS PROJECTS – ETARGETEDBCP (R21)

NIH: National Institutes of Health

This supports research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behaviour. Application budgets are worth up to USD 275,000 for a two-year period. No more than USD 200,000 may be requested in any single year.

Closing date: 08 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-015.html

BRAIN INITIATIVE: TARGETED BRAIN CIRCUITS PROJECTS – TARGETEDBCP (R01)

NIH: National Institutes of Health

This supports research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behaviour. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 08 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-17-014.html

INTEGRATED PRECLINICAL AND CLINICAL AIDS VACCINE DEVELOPMENT PROGRAMME (U19)

NIH: National Institute of Allergy and Infectious Diseases

This announcement aims to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing. NIH intends to commit approximately US$2.8 million in fiscal year 2017 to fund one to two awards. Application budgets are expected to be between US$1.5m and US$2.5m per year. The maximum project period is five years.

Closing date: 09 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-330.html

CORE INFRASTRUCTURE AND METHODOLOGICAL RESEARCH FOR CANCER EPIDEMIOLOGY COHORTS (U01)

NIH: National Cancer Institute

This announcement provides targeted infrastructure support for the core functions of cancer epidemiology cohorts and methodological research. The maximum budget is US$2.5 million in direct cost per year. The maximum project period is five years.

Closing date: 10 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-104.html

PILOT CLINICAL TRIALS TARGETING HIV-1 RESERVOIRS IN CHILDREN (U01)

NIH: National Institute of Allergy and Infectious Diseases

This supports pilot clinical trials that test interventions to limit or reduce HIV-1 reservoirs in children, from birth to 18 years of age, on effective suppressive antiretroviral therapy. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 14 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-086.html

PLANNING FOR NON-COMMUNICABLE DISEASES AND DISORDERS RESEARCH TRAINING PROGRAMMES IN LOW AND MIDDLE INCOME COUNTRIES (D71)

NIH: Fogarty International Center

This announcement supports LMIC institutions with existing research and research training capacity in chronic, non-communicable diseases and disorders, and aims to develop a plan for a research training programme within the LMICs that will further strengthen the capacity of LMIC individuals, institutions and countries to identify NCD and disorders priorities, and conduct research across the lifespan. Application budgets are worth up to USD 46,000 for a maximum period of one year.

Closing date: 14 Mar 17
Website:
https://grants.nih.gov/grants/guide/pa-files/PAR-17-097.html

BRAIN INITIATIVE FELLOWS: RUTH L KIRSCHSTEIN NATIONAL RESEARCH SERVICE AWARD INDIVIDUAL POSTDOCTORAL FELLOWSHIP (F32)

NIH: National Institute of Mental Health

This aims to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Award budgets are composed of stipends, tuition, fees and institutional allowance

Closing date: 15 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-250.html

SYSTEMS BIOLOGY: THE NEXT GENERATION FOR INFECTIOUS DISEASES (U19)

NIH: National Institute of Allergy and Infectious Diseases

This aims to establish systems biology centres that use systems biology approaches to build predictive models for infectious diseases. The total budget is worth USD 11 million to fund up to five awards in fiscal year 2018. Application budgets are worth up to USD 2m per year for a maximum period of five years.

Closing date: 15 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-080.html

DEVELOPMENT OF MULTIPURPOSE PREVENTION TECHNOLOGIES: A STRATEGY FOR THE PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS (R61/R33)

NIH: National Institute of Allergy and Infectious Diseases

This supports translational research focused on development of multipurpose prevention technologies for prevention of sexually transmitted infections, human immunodeficiency virus and unintended pregnancy. Application budgets are worth up to USD 300,000 in direct costs per year, for a maximum period of five years.

Closing date: 15 Mar 17
Website:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-085.html

SMALL-CELL LUNG CANCER CONSORTIUM: THERAPEUTIC DEVELOPMENT AND MECHANISMS OF RESISTANCE (U01)

NIH: National Cancer Institute

This announcement aims to establish research teams of the small cell lung cancer consortium to conduct research whose overall goals are to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations and to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy. Application budgets are limited to US$450,000 per year for up to five years.

Closing date: 17 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-049.html

SMALL-CELL LUNG CANCER CONSORTIUM: INNOVATIVE APPROACHES TO THE PREVENTION AND EARLY DETECTION OF SMALL CELL LUNG CANCER (U01)

NIH: National Cancer Institute

This announcement aims to establish research teams of the small cell lung cancer consortium to conduct research whose overall goals are to expand the understanding of the critical molecular changes in the lung that precede the development of frank SCLC and to identify the populations at particularly high risk for SCLC. Application budgets are limited to US$450,000 in direct costs, excluding consortium facilities and administration costs, per year. The maximum project period is five years.

Closing date: 17 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-051.html

NINDS EXPLORATORY CLINICAL TRIALS (R01)

NIH: National Institute of Neurological Disorders and Stroke

This supports investigator-initiated exploratory clinical trials. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 21 Mar 17
Website:
https://grants.nih.gov/grants/guide/pa-files/PAR-17-122.html

CLINICAL AND TRANSLATIONAL EXPLORATORY OR DEVELOPMENTAL STUDIES (R21): AIDS-RELATED

NIH: National Cancer Institute

This Aids-related call supports new exploratory research in cancer diagnosis, treatment, imaging, symptom or toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom or toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies. Application budgets are limited to USD 275,000 in direct costs per year for the maximum period of two years. No more than USD 200,000 may be requested in any single year.
Closing date: 22 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-176.html

THERAPEUTIC TARGETING OF THE HUMAN ISLET ENVIRONMENT (UC4)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This aims to develop strategies to target the human pancreatic environment in-vivo to deliver cell-based therapeutics, regulatory molecules or gene constructs that can protect or replenish the functional beta cell mass, or to develop synthetic sentinel biomarkers to safely monitor beta cell stress or disease initiation prior to the appearance of autoantibodies in individuals at risk of developing type 1 diabetes. Application budgets are worth up to USD 600,000 per year for maximum period of four years.
Closing date: 22 Mar 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-003.html

COMPETITIVE COLLABORATIVE PROJECTS FOR HUMAN ISLET BIOLOGY (UC4)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports collaborative research projects aiming to increase the understanding of how human beta cells are lost in type 1 diabetes and finding innovative strategies to protect or replace functional beta cell mass in diabetic patients. Application budgets are limited to USD 350,000 per year for maximum period of four years.
Closing date: 23 Mar 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-004.html

SECONDARY ANALYSES OF EXISTING DATASETS IN HEART, LUNG AND BLOOD DISEASES AND SLEEP DISORDERS (R21): AIDS-RELATED

NIH: National Heart, Lung and Blood Institute

This Aids-related call aims to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioural research in areas relevant to the NHLBI mission. Application budgets are worth up to USD 150,000 for a two year period. No more than USD 75,000 is allowed in any single year.
Closing date: 24 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-17-004.html

STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)

NIH: National Institute on Drug Abuse

This call supports research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organisations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Application budgets are worth up to USD 3 million per year for maximum period of three years.
Closing date: 27 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-430.html

GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)

NIH: National Institute on Drug Abuse

This call aims to accelerate the development of medication for the treatment of substance-use disorders by encouraging research applications to support a diverse array of preclinical and clinical research projects. Two to three awards per year, each worth up to USD 5 million per year for a maximum period of three years, are available.
Closing date: 27 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-16-431.html

FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3)

NIH: National Institute on Drug Abuse

This announcement aims to accelerate the discovery and development of medications to treat cannabis use disorders. Application budgets are limited to US$1 million in directs costs per year. The maximum project period is two years for the UG3 phase and three years for the UH3 phase.

Closing date: 28 Mar 17
Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-15-267.html

MOVING BEYOND STANDARD ASSESSMENTS: APPLYING NOVEL TOOLS TO ASSESS HUMAN PLACENTAL STRUCTURE AND FUNCTION IN REAL TIME (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports novel approaches for the development of safe, real-time, non-invasive or minimally invasive, in vivo methods to assess the development and function of the human placenta across pregnancy. Application budgets are worth up to USD 499,000 in direct costs per year for maximum period of five years.

Closing date: 31 Mar 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-18-003.html

MOVING BEYOND STANDARD ASSESSMENTS: APPLYING NOVEL TOOLS TO ASSESS HUMAN PLACENTAL STRUCTURE AND FUNCTION IN REAL TIME (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports novel approaches for the development of safe, real-time, non-invasive or minimally invasive, in vivo methods to assess the development and function of the human placenta across pregnancy. Application budgets are worth up to USD 275,000 for maximum period of two years. No more than USD 200,000 may be requested in any single year.

Closing date: 31 Mar 17
Website:
https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-18-004.html